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Abstract 
 
The goal of this research was to identify the differential structure-activity 
relationships between cytochromes P450 (CYP) 2A13 and 2A6 and their substrates.  
Cytochromes P450 2A13 and 2A6 are very closely related, having 94% amino acid 
sequence identity.  Both proteins metabolize drugs, toxins, and procarcinogens, 
including the nicotine derivative 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and aflatoxin B1.  Yet CYP2A13 has a much higher rate of metabolism than 
CYP2A6 for both compounds.  Combined with its increased affinity and expression 
in the respiratory tract, CYP2A13 is a candidate for breakdown of NNK into the 
reactive metabolites that can form DNA adducts in the lung, leading to the 
development of lung cancer (1).  Thus, understanding differential metabolism is 
important.  Due to the high identity of CYP2A13 and CYP2A6, we hypothesized that 
a few amino acids found within the active site are responsible for CYP2A substrate 
specificity.  Of the 32 amino acids which differ between CYP2A13 and CYP2A6, ten 
are located in regions of the protein that often determine substrate recognition in 
cytochromes P450 (2).  Crystallization of CYP2A13 by the Scott lab verified that 
these amino acids were in or near the active site.  The goal of this project was to 
determine which of these ten amino acids were vital for substrate selectivity in the 
CYP2A enzymes. 
  Several different methods were employed throughout this study including 
site-directed mutagenesis, ligand binding assays, metabolism assays, molecular 
modeling, and crystallography.  Site-directed mutagenesis was used to construct ten 
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single residue CYP2A13 mutants with each mutation substituting the residue found in 
CYP2A6 in that position.  The consequences of these ten mutations to the binding of 
coumarin, 2′-methoxyacetophenone, phenyl isothiocyanate, and phenacetin were 
determined using spectral ligand binding assays.  The amino acids in positions 117, 
208, 300, 301, 365, and 369 caused significant changes in ligand affinity.  To 
determine if these amino acids were also essential for substrate metabolism, 
phenacetin was used as a structural probe since CYP2A6 converts phenacetin to 
acetaminophen with decreased catalytic efficiency compared to CYP2A13 (3).  
Employing this assay, four mutations (S208I, F300I, A301G, and G369S) were 
identified that diminished CYP2A13 phenacetin O-deethylation to near CYP2A6 
activity. Two mutants, CYP2A13 A117V and L366I, both increased enzyme activity 
more than four-fold.  Construction of the reverse mutant series, a CYP2A6 protein 
incorporating the residues found at the corresponding active site positions in 
CYP2A13, confirmed that positions 208, 300, 301, and 369 were jointly responsible 
for phenacetin metabolism and binding.  While all single 2A6 mutants had very low-
level activity, the double, triple, and a quadruple mutant with changes at these four 
positions increasingly conferred phenacetin metabolism to CYP2A6. 
A structural basis for the effects of these four mutations on phenacetin binding 
and metabolism was explored with molecular docking studies using Surflex-Dock (4).  
The results suggested that the ability of CYP2A13 to bind and metabolize phenacetin 
was due to steric variations among key residues in the CYP2A13 and CYP2A6 active 
  v 
sites.  This was confirmed with the crystal structure of the CYP2A6 
I208S/I300F/G301A/G369S complexed with phenacetin.  
Finally, this study characterized the effects of naturally occurring CYP2A13 
polymorphisms on the binding of the well-known CYP2A ligand coumarin (5).  All 
of these polymorphisms were located on the exterior portions of the protein.  None of 
the polymorphisms examined resulted in a significant change in ligand affinity, 
indicating that having one of these variants would not substantially alter an 
individual’s ability to metabolize CYP2A13 substrates.   
 Thus, the research presented in this thesis provides structural and functional 
insight into CYP2A13 and CYP2A6 substrate selectivity, which is largely modulated 
by the steric effects mediated by the differential amino acids at positions 208, 300, 
301, and 369.  
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Please Note: 
 The CYP2A13 polymorphism data presented in this paper was previously 
published as a joint publication from the Scott and Murphy labs in 2007 by Kari E. 
Schlicht, Natasha M. Michno, Brian D. Smith, Emily E. Scott, and Sharon E. Murphy 
in Xenobiotica as a “Functional characterization of CYP2A13 polymorphisms.”  The 
phenacetin binding, metabolism, docking, and the crystal structure of CYP2A13 
I208S/I300F/G301A/S369G are included in the article “Key Residues Controlling 
Phenacetin Metabolism by Human Cytochrome P450 2A Enzymes” currently in press 
by Drug Metabolism and Distribution.  The article is by Natasha M. DeVore, Brian 
D. Smith, Michael J. Urban, and Emily E. Scott. 
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Chapter 1. 
 
Introduction 
 
Introduction: Cytochromes P450 
 Cytochrome P450 enzymes are the primary enzymes responsible for Phase I 
metabolism of drugs and other xenobiotics.  In this process, a foreign small molecule 
is modified to decrease hydrophobicity.  There are a number of reactions catalyzed by 
P450s that increase the hydrophilicity of a substrate molecule, including both 
oxidative and reductive pathways.  In addition to xenobiotics, cytochrome P450 
substrates include sterols, fatty acids, eicosanoids, and vitamins (1).  However, the 
cytochromes P450 that metabolize xenobiotics are of particular interest due to their 
importance in drug metabolism and their possible role activating protoxins and 
procarcinogens.   
Cytochromes P450 were first identified by Garfinkel and Klingenberg in 1958 
by noting a characteristic absorption maximum at 450 nm on a UV spectra after the 
addition of carbon monoxide into a solution of buffer containing the heme protein and 
a strong reducing agent such as dithionite (Figure 1.1) (2).  Since that time, much 
research has been conducted into the expression, structure, and function of 
cytochrome P450 enzymes.  
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Figure 1.1.  P450 carbon monoxide difference assay spectra.  When 
CO is bubbled into a solution of P450 containing dithionite, CO binds 
to the P450 heme resulting in a spectral shift from 420 nm to 450 nm. 
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Human cytochromes P450 are primarily found in the liver, although they are 
also found in the kidney, respiratory system, gonads, pancreas, spleen, 
gastrointestinal tract, and skin (3).  The expression location and amount of 
cytochrome P450 protein produced is highly dependent on the enzyme in question 
and often differs in response to xenobiotic exposure (4,5).  Therefore, levels are often 
highly variable between individuals. 
Cytochrome P450 Nomenclature 
 Cytochromes P450 are divided into 135 families.  Each family is defined by 
having at least 40% amino acid identity among members (6,7).  Separate families are 
indicated by Roman numerals.  Families 1, 2, and 3 are involved in the metabolism of 
xenobiotics and, as such, are particularly important in drug metabolism studies 
(Figure 1.2) (1,7).  Each family is sub-divided into subfamilies that share at least 55% 
identity and are represented by capital letters (7).  Individual P450 isozymes are then 
assigned a second Roman numeral, indicative of the particular enzyme.  For example, 
CYP2A13 belongs to family 2 and subfamily A.  If a variant allele exists for an 
established cytochrome, it is named by a star followed by a number, for example 
CYP3A5*2 (8).   
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Figure 1.2. The three human cytochrome P450 families involved in xenobiotic 
metabolism. 
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The Cytochrome P450 Catalytic Cycle 
 The xenobiotic cytochrome P450 enzymes are able to metabolize a substrate 
via a metal ion catalysis cycle.  The primary features of this cycle are conserved 
between cytochromes P450.  The main features of the catalytic cycle include: 
substrate binding, oxygen binding, oxygen scission, oxygen insertion into the 
substrate, and product release (Scheme 1.1).    
The Human Cytochrome P450 2A subfamily 
 There are three cytochrome P450 enzymes belonging to the human CYP2A 
subfamily: CYP2A6, CYP2A13, and CYP2A7.  All three members of the 2A family 
are located on human chromosome 19 in a cluster that also includes the genes for 
CYP2F1, CYP2B7, and CYP2B6 (Figure 1.3) (9,10).  The CYP2A family is known 
for its ability to metabolize xenobiotics, and its substrates include several toxins and 
procarcinogens: aflatoxin B1, 4-aminobiphenyl, and the nicotine derivative 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).   
CYP2A6 is the most studied of the three enzymes because it constitutes 5-
10% of the total microsomal cytochrome P450 in the human liver (11,12).  The 
CYP2A6 enzyme was identified along with two variants and CYP2A7 in 1989 by 
Yamano et al (12). CYP2A6 was identified as the main enzyme responsible for 
coumarin 7-hydroxylation in humans while the two variants identified at the same 
time had severely reduced coumarin 7-hydroxylation levels and CYP2A7 had no 
activity (12).  Coumarin 7-hydroxylation was at higher levels in human liver than in 
several animal species and coumarin was identified as a potential cytochrome P450  
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Scheme 1.1.  The catalytic cycle of cytochromes P450.  1)  A water molecule is 
bound to the Fe atom.  2) A ligand binds in the active site of the P450, displacing 
the water molecule. 3) An electron from NADPH is delivered to the iron (by 
NADPH cytochrome P450-oxidioreductase) reducing the iron to the ferrous 
form. 4) Molecular oxygen binds to the reduced iron atom.  5) A second electron 
is transferred to the system by either P450-oxidoreductase or cytochrome b5 
which reduces the complex to a peroxoanion intermediate.  6)  The terminal 
oxygen atom binds a proton.  7)  A second proton is bound to the terminal 
oxygen atom, which then leaves as water.  The other atom of oxygen is left 
bound to the iron, probably as compound I.  At this point the remaining oxygen 
is able to abstract a hydrogen from the substrate, and then rebound to the 
substrate as a hydroxyl group.  The substrate may then undergo further 
rearrangement to form the final product. 
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substrate years before CYP2A6 was even discovered (13).  The level of 2A6 
expression in human liver samples is highly variable, consistent with the observed 
variation in coumarin 7-hydroxylation between human liver microsomes (12-14).  In 
addition to the metabolism of coumarin, CYP2A6 is also able to metabolize a diverse 
range of substrates including indoles, nicotine, the gasoline additive methyl tert-butyl 
ether (MTBE), and N-nitrosodiethylamine (NDEA) (11,15).  Known inhibitors of 
CYP2A6 include several isothiocyanates, the monoamine oxidase inhibitor 
tranylcypromine, 8-methoxysporalen, and the antifugal ketoconazole (16-18). 
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2F1 2F1 2F1 2A13 2A6 2A7 2A7 2A7 2B7 2B7 2B6 
Centromere   350 Kb   Telomere 
 
Figure 1.3. Organization of the human cytochrome P450 family 2 genes on 
chromosome 19.   The diagram above is a 350 Kb cluster with the centromere and 
telomere labeled, and the direction of transcription indicated by arrows above the 
respective genes.  Underlines indicate pseudogenes.  This figure was redrawn from 
Fernadex-Salguero et al. (1995). 
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CYP2A7 was identified at the same time as CYP2A6 (14).  CYP2A7 has a 
94% sequence identity with CYP2A6, differing by 31 amino acids out of 494, and is 
located next to CYP2A6 on chromosome 19 (Figure 1.3) (10,12,14).  Two 
psuedogenes have been identified that are alternate spliced forms of CYP2A7 (9).  
Several variants of CYP2A6 have also been identified which seem to have resulted 
from gene crossover events between the CYP2A6 and CYP2A7 genes (9).  Early 
efforts at the expression of CYP2A7 were inconclusive as to whether or not CYP2A7 
mRNA could produce active protein.  Yamano and coworkers expressed CYP2A7 in 
the vaccinia virus (12).  However, only small amount of immunostained protein band 
was generated as identified by SDS page gel using a rat CYP2A2 antibody (12).  In 
addition, cells infected with this recombinant virus after 24 hours failed to show the 
characteristic CYP450 Soret shift from 420 nm to a maxima of ~450 nm upon the 
addition of dithionite and carbon monoxide (Figure 1.1).  Ding and coworkers cloned 
CYP2A7 cDNA into a pCMV4 vector and transfected it into COS cells (14).  They 
were able to obtain a CYP2A7 protein with a molecular mass of 49kDa as indicated 
by Western-blot analysis, but addition of coumarin to the cells failed to produce a 
measurable amount of 7-hydroxycoumarin, the distinctive coumarin metabolite 
usually produced by CYP2A enzymes (14).  Ding and coworkers did not report CO 
difference assay results, so it is impossible to know if folded, active CYP2A7 was 
present. Since these initial studies, very little research has been conducted on 
CYP2A7 and so the activity of the protein remains unknown.  CYP2A7 is currently 
labeled as an orphan human cytochrome P450 (1). 
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The CYP2A13 gene was identified when the 2A genes were fully sequenced 
in 1995 (9,10).  CYP2A13 has a 94% amino acid identity with CYP2A6, differing by 
32 amino acids out of 494.  The enzyme was not characterized until nearly five years 
later when Su et al. determined that CYP2A13 was primarily expressed within the 
respiratory tract, with the highest level of mRNA present in nasal mucosa, and had 
activity toward NNK, coumarin, and several other CYP2A6 substrates (19). Since 
that time, several more substrates have been identified.  Isothiocyanates and 8-
methoxysporalen are potent inhibitors for both CYP2A13 and CYP2A6 (17,18,20).  
Expression levels of CYP2A13 within the respiratory system vary between 
individuals (21).  Primary interest in the enzyme stems from its location in the 
respiratory system and ability to metabolize NNK and aflatoxin B1 to carcinogens 
with a higher efficiency than CYP2A6.   
Polymorphisms 
 Each of the CYP2A family enzymes have several polymorphisms.  Many of 
the CYP2A6 polymorphisms vary with ethnicity and may contribute to both smoking 
behavior and cancer incidence (22-25).   Several of the CYP2A6 polymorphisms are 
alterations of a single amino acid, yet these polymorphisms can result in significantly 
reduced nicotine metabolism (Table 1.1).   Although less is known about CYP2A7, 
several splice variants of both CYP2A6 and CYP2A7 have been identified that have 
either no or severely reduced catalytic activity (14,23).   
The polymorphisms of CYP2A13 have been studied less than those of 
CYP2A6.  Fujieda and coworkers identified 18 novel non-synonymous 
 11 
polymorphisms in CYP2A13, however, the functional significance of the many of the 
single amino acid polymorphisms identified was unknown (26,27).   One aspect of 
my research has been a collaboration to identify the functional significance of seven 
CYP2A13 polymorphisms (R257C, F453Y, R494C, D158E, V323L, R101Q, 
133_134Thr insertion) using NNK and coumarin metabolism assays and coumarin 
spectral binding assays (28).  Prior to our investigation, only the CYP2A13 variants 
R257C and R101E had been characterized as purified proteins (27,29).    
 12 
Table 1.1. CYP2A6 non-synonymous polymorphisms and known functional effects. 
 
Allele Protein Change Functional Change 
CYP2A6*2 L160H Alters coumarin metabolism to coumarin 3-
hydroxylation instead of coumarin 7-hydroxylation 
(30) 
CYP2A6*3 CYP2A6/CYP2A7 
hybrid 
Decreased coumarin metabolism in vitro (31) 
CYP2A6*4 CYP2A6 deleted 
(32) 
Unknown 
CYP2A6*5 G479V Decreased coumarin metabolism in vitro (31) 
CYP2A6*6 R128Q Decreased coumarin metabolism (33) 
CYP2A6*7 I471T Decreased activity for nicotine and coumarin (34) 
CYP2A6*8 R485L No effect on coumarin or nicotine metabolism (34) 
CYP2A6*9 A-1013G and T-48G Reduced coumarin metabolism (35) 
CYP2A6*10 I471T and R485L Absent or reduced catalytic activity for nicotine 
and coumarin (34) 
CYP2A6*11 S224P Reduced tegafur metabolism (36) 
CYP2A6*12 CYP2A6/CYP2A7 
hybrid 
Reduced coumarin metabolism (37) 
CYP2A6*13 T48G and G5R Unknown 
CYP2A6*14 S29N Unknown 
CYP2A6*15 T48G and K194E Unknown 
CYP2A6*16 R203S No effect on coumarin or nicotine metabolism (38) 
CYP2A6*17 V365M Decreased nicotine and coumarin metabolism 
(38,39) 
CYP2A6*18 Y392F Decreased coumarin and tegafur clearance (40) 
CYP2A6*19 Y392F and I471T Decreased metabolic activity for coumarin and 
tegafur (40) 
CYP2A6*20 Frame Shift, 
truncation 
No activity for coumarin or nicotine (41) 
CYP2A6*21 K476R No affect on nicotine metabolism (42) 
CYP2A6*22 D158E and L160I Unknown 
CYP2A6*23 R203C Reduced nicotine and coumarin metabolism (38) 
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Substrate Selectivity 
 Consistent with the close amino acid identity, CYP2A13 and CYP2A6 have a 
substantial overlap in substrate selectivity.  Both proteins are able to metabolize a 
wide range of substrates including coumarin, nicotine, aflatoxin B1, and the nicotine 
procarcinogen NNK (11,43,44).  Many CYP2A6 and CYP2A13 substrates are planar 
cyclic molecules, but there are a number of exceptions including methyl t-butyl ether, 
N-nitrosodiethylamine (NDEA), and halothane (2,11).  Although there is considerable 
substrate overlap, the difference in the rate of metabolism can be considerable for 
individual substrates between CYP2A6 and CYP2A13.  Depending on the report, 
CYP2A13 has a catalytic efficiency for NNK that is 75 - 215 times greater than that 
of CYP2A6 (19,45).  Furthermore, CYP2A13 has 22- and 15-fold greater catalytic 
efficiency for nicotine C-oxidation and cotinine 3´-hydroxylation than CYP2A6, 
respectively (46).  There is also considerable variation in the metabolism of coumarin, 
hexamethylphosphoramide, N,N-dimethylaniline, 2´-methoxyacetophenone, and N-
nitrosomethylphenylamine (19).  Furthermore, although both CYP2A6 and CYP2A13 
metabolize aflatoxin B1, only CYP2A13 metabolizes aflatoxin B1 into a mutagenic 
epoxide (43).  
 Two substrates, the antipyretic drug phenacetin and procarcinogen 4-
aminobiphenyl, are metabolized by CYP2A13 while CYP2A6 barely has detectable 
activity with these substrates (47,48).  CYP2A13 is not the only cytochrome P450 
that metabolizes phenacetin and 4-aminobiphenyl, as the CYP family 1 also 
metabolizes these substrates.  CYP2A13 metabolizes 4-aminobiphenyl with a 8-fold 
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decrease in catalytic efficiency and phenacetin with a 2.5-fold higher efficiency 
compared to CYP1A2 (47,48).  The overlap in substrate metabolism between 
CYP2A6, CYP2A13, and CYP1A2 is of particular interest because CYP2A13 and 
CYP1A1, closely related to CYP1A2, are both found primarily in the lung (4).  In 
contrast, CYP2A6 and CYP1A2 are expressed primarily in the liver.   
CYP2A6 and CYPA13 Structure and Active Site 
The overall structure of CYP2A13 closely resembles that of CYP2A6, with an 
average root mean square deviation of 0.5 Å for the Cα atoms (49).  Both enzymes 
contain twelve major α helices, which are labeled A-L (Figure 1.4).  The I helix spans 
the length of the entire cytochrome P450 structure, with a small kink in the helix near 
the iron protoporphyrin IX prosthetic group. The iron atom of the protoporphyrin IX 
coordinates to C439, located in the K′-L loop, just below the heme.  Several 
additional hydrogen bonds and hydrophobic interactions with the surrounding loop 
and helix residues occur to stabilize the location of the heme.  The active site is found 
above the heme.  Although direction in an enzyme is arbitrary, throughout the rest of 
this thesis the floor of the active site will refer to the heme, while the ceiling of the 
active site is formed I helix and F helix residues as well as a few residues from the K- 
K′ and B′-C loop.  The walls of the active site are formed by the I helix, and the K- K′ 
and B′-C loops. 
Some differences are seen in the in the active site architecture of the two 
CYP2A enzymes (49). These differences account for an active site in CYP2A13 
which is 15-20% larger than the active site of CYP2A6, which is one of the smallest  
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Figure 1.4.  The crystal structure of human cytochrome P450 2A13 (PDB 
2P85).  Helices are labeled A-L.  The heme is colored red. 
 16 
identified P450 active sites (49). The active site volume for CYP2A13 is reported as 
307 Å3, a volume intermediate to that of CYP2A6 (260 Å3) and CYP1A2 (375 Å3) 
(49,50). CYP2A13 and CYP2A6 both have relatively small active sites which are 
planar, highly hydrophobic, and compact, therefore complimenting aromatic 
substrates (49,50).  There are a number of amino acids located in or near the active 
site that differ between CYP2A6 and CYP2A13 (Figure 1.4).  Crystal structures 
suggest that these differences could alter ligand binding and orientation within the 
two active sites (49).  Although the crystal structures for CYP2A13 and CYP2A6 do 
not have the same ligand present, the coumarin bound in CYP2A6 and the indole 
bound in the CYP2A13 structure are bound in a similar location with respect to the 
heme and hydrogen bonding to N297 but adapt different planes (49).  Several of the 
amino acids within the active site could be responsible for the ligand reorientation 
(Figure 1.4).  These include the nearby amino acids at positions 208, 300, 301, 117, 
365, and 366.  Of particular interest is residue 300.   In CYP2A13, phenylalanine 300 
is positioned away from the ligand, while the isoleucine in CYP2A6 is directed into 
the active site (49).  The amino acid at position 301 also differs, an alanine in 
CYP2A13 and a glycine in CYP2A6, potentially resulting in increased steric 
hindrance for ligand binding and orientation within the CYP2A13 active site.   
Mutagenesis studies have shown that substitution of the alanine found at 
position 117 in CYP2A13 to the valine found in CYP2A6 creates a CYP2A13 mutant 
with increased activity for formation of 7-hydroxycoumarin, decreased activity for 
the formation of the NNK keto aldehyde metabolite, and increased metabolism of 
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aflatoxin B1 to the harmful epoxides  (43-45).  Located on one wall of the CYP2A13 
and CYP2A6 active site, it appears that the difference in space occupied by the 
alanine in CYP2A13 and the valine in CYP2A6 substantially affects the rate of 
metabolism for these two substrates (43-45,49).  Site directed mutagenesis studies at 
the 208 position indicate that this residue may contribute to substrate specificity as 
studies have indicated that the 208 position is important for the metabolism of NNK 
but not coumarin (44,45).   
Previous site directed mutagenesis studies also indicated that the histidine to 
arginine change at residue 372 in CYP2A13 decreases the substrate kcat for couarmin 
7-hydroxylation, decreases the NNK metabolism to both the aldehyde and keto 
metabolites, and abolishes the production of aflatoxin B1 epoxides (43-45).  The 372 
position is further away from the substrate in the active site (Figure 1.4).   
Active site differences between the amino acids at positions 365 and 366 
could also affect substrate selectivity.  These two positions are located across from 
the I helix (Figure 1.5).  The methonine at position 365 in CYP2A13 is much longer 
than the corresponding valine in CYP2A6, resulting in the greater projection of this 
residue into the active site cavity in CYP2A13 (49).  The leucine found in CYP213 
also projects more into the active site than the isoleucine side chain at this position in 
CYP2A6.  Thus, reorientation of the ligand in the active site as a result of several 
amino acid differences, including those at positions 208, 300, 301, 365, and 366 may 
mediate the observed differences in substrate binding and metabolism.   
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Figure 1.5.  Structure of CYP2A13 (green, PDB 2P85) and CYP2A6 (brown, PDB 
1Z10) overlaid with ligands removed.  Residues that differ between CYP2A13 and 
CYP2A6 are represented by sticks and labeled (e.g. A117V – Ala found in 
CYP2A13, Val found in CYP2A6).   
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Project Goals and Hypothesis 
 The main goal of this study is to determine the structural divergence in the 
two very closely related human cytochromes P450 CYP2A13 and CYP2A6 
responsible for enzyme function differences.  We hypothesize that amino acids 
located near or in the active site that differ between CYP2A13 and CYP2A6 were 
most likely to control functional differences.  To test this we have employed site-
directed mutagenesis to exchange the amino acids that differ between the enzyme 
active sites and characterized the mutants for their ligand binding and metabolism 
abilities.  We first characterized binding with a set of four CYP2A ligands, and then 
focused on the metabolism of phenacetin, a substrate metabolized by CYP2A13 and 
not by CYP2A6.  Structural insight into the significance of various mutations was 
acquired by docking and X-ray crystallography. Collectively the crystal structures, 
phenacetin metabolism data, and ligand binding information provide valuable 
structural and function insight into the CYP2A proteins. 
In addition, several polymorphisms that were previously identified for 
CYP2A13 were characterized for their coumarin binding affinity as a part of this 
project (26-29,51).  Identifying and studying the effects of CYP2A polymorphisms on 
enzyme function is important to accessing nicotine and NNK metabolism and cancer 
risk. 
Experimental Design 
Rational Site-directed Mutagenesis.  In order to determine the amino acids 
responsible for substrate selectivity, a series of ten mutants were constructed that 
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were identical to CYP2A13 except for one amino acid at a position where CYP2A13 
and CYP2A6 did not have the same residue.  These CYP2A13 mutants were: L110V, 
A117V, S208I, A213S, F300I, A301G, M365V, L366I, G369S, and H372R.  This 
initial series of ten mutants was later expanded to include ten reverse single point 
mutations in the CYP2A6 background (V110L, V117A, I208S, S213A, I300F, 
G301A, V365M, I366L, S369G, and R372H) and several CYP2A6 multiple mutants 
combining these individual alterations.   
At the initiation of this project, no crystal structures of the CYP2A enzymes 
were available, so the ten residues to mutate were selected based on sequence 
alignments between CYP2A13 and CYP2A6 and location within the previously 
postulated substrate recognition sites (SRS) in the cytochrome family 2 enzymes 
(Figure 1.6) (53).  Residues found in these recognition sites are affiliated with 
differences in substrate selectivity in other cytochrome P450 enzymes. We 
hypothesized that residues within substrate recognition sites that differed between the 
two CYP2A enzymes may mediate the variation in CYP2A function.   
During the course of this study, crystal structures for both CYP2A13 and 
CYP2A6 were determined by the Scott lab and the Johnson lab, respectively (49,54).  
The proximity of the residues selected for this study to the active site is verified by 
these structures (Figure 1.7).  Two residues that were mutated (L110 and A117) are 
located in SRS-1.   L110 is located above the active site, while A117 forms part of the 
active site wall.  The residues S208 and A213 are both located in SRS-2.  Residue 
A213 is located at the terminus of the F helix while S208 is located in the F helix 
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above F300.  Residues F300 and A301 were also mutated and both are located in 
SRS-4 on the I helix.  All of the other mutations made are located in SRS-5 and form 
part of the active site cavity across from the I helix.  These residues are M365, L366, 
G369, and H372.  H372 is located further from the active site, and is involved in the 
hydrogen bonding to the heme proprionate. 
The wild type and mutant CYP2A13 and CYP2A6 proteins were expressed in 
E. coli and purified by nickel affinity and carboxymethyl sephrose ion exchange 
chromatography.  Differences in ligand binding (phenacetin, 2`-
methoxyacetophenone, phenethyl isothiocyanate, and coumarin) and phenacetin 
metabolism studies indicated residues that are involved in CYP2A affinity and 
metabolism.  The effects of these mutations were interpreted in conjunction with 
molecular docking experiments.  Finally, the structure of the quadruple mutant 
CYP2A6 I208S/I300F/G301A/S369G complexed with phenacetin was determined. 
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   2A6  MLASGMLLVA LLVCLTVMVL MSVWQQRKSK GKLPPGPTPL PFIGNYLQLN  
  2A13  MLASGLLLVT LLACLTVMVL MSVWRQRKSR GKLPPGPTPL PFIGNYLQLN  
2A13dH  MA~~~~~~~~ ~~~~~~~~~~ ~~~~KKTSSK GKLPPGPTPL PFIGNYLQLN  
                                                          A' 
           51                                                                      100 
   2A6  TEQMYNSLMK ISERYGPVFT IHLGPRRVVV LCGHDAVREA LVDQAEEFSG  
  2A13  TEQMYNSLMK ISERYGPVFT IHLGPRRVVV LCGHDAVKEA LVDQAEEFSG  
                 A           β1-1         β1-2              B          β1- 
           101  SRS-1                                                              150 
   2A6  RGEQATFDWV FKGYGVVFSN GERAKQLRRF SIATLRDFGV GKRGIEERIQ  
  2A13  RGEQATFDWL FKGYGVAFSN GERAKQLRRF SIATLRGFGV GKRGIEERIQ  
               B'                     C                     D 
          151                                                                      200 
   2A6  EEAGFLIDAL RGTGGANIDP TFFLSRTVSN VISSIVFGDR FDYKDKEFLS  
  2A13  EEAGFLIDAL RGTHGANIDP TFFLSRTVSN VISSIVFGDR FDYEDKEFLS  
                                        E                    F 
           201  SRS-2       SRS-2                  250 
   2A6  LLRMMLGIFQ FTSTSTGQLY EMFSSVMKHL PGPQQQAFQL LQGLEDFIAK  
  2A13  LLRMMLGSFQ FTATSTGQLY EMFSSVMKHL PGPQQQAFKE LQGLEDFIAK  
                          F'      G'                  G 
           251              SRS-4    300 
   2A6  KVEHNQRTLD PNSPRDFIDS FLIRMQEEEK NPNTEFYLKN LVMTTLNLFI  
  2A13  KVEHNQRTLD PNSPRDFIDS FLIRMQEEEK NPNTEFYLKN LVMTTLNLFF  
                               H                             
           301                                                                     350 
   2A6  GGTETVSTTL RYGFLLLMKH PEVEAKVHEE IDRVIGKNRQ PKFEDRAKMP  
  2A13  AGTETVSTTL RYGFLLLMKH PEVEAKVHEE IDRVIGKNRQ PKFEDRAKMP  
   I      J                 J’  K 
           351         SRS-5                                          400 
   2A6  YMEAVIHEIQ RFGDVIPMSL ARRVKKDTKF RDFFLPKGTE VYPMLGSVLR  
  2A13  YTEAVIHEIQ RFGDMLPMGL AHRVNKDTKF RDFFLPKGTE VFPMLGSVLR  
               K               β1-4    β2-1   β2-2     β1-3    K' 
           401                                                                     450 
   2A6  DPSFFSNPQD FNPQHFLNEK GQFKKSDAFV PFSIGKRNCF GEGLARMELF  
  2A13  DPRFFSNPRD FNPQHFLDKK GQFKKSDAFV PFSIGKRYCF GEGLARMELF  
                       K”                                 L 
           451       SRS-5                      494 
   2A6  LFFTTVMQNF RLKSSQSPKD IDVSPKHVGF ATIPRNYTMS FLPR 
  2A13  LFFTTIMQNF RFKSPQSPKD IDVSPKHVGF ATIPRNYTMS FLPR 
                   β3-3     L'       β4-1    β4-2      β3-2  HHHH 
 
Figure 1.6.  P450 2A6 and P450 2A13 amino acid sequence alignment completed with CL 
Workbench.  P450 2A13dH (third line on first row of sequence alignment) is the sequence for 
the truncated CYP2A13 enzyme, ~ indicates a deletion.  The 32 amino acid differences are 
highlighted in bold.  The ten residues mutated in this study are colored red.  The site of 
polymorphisms studied in CYP2A13 are colored pink.  The secondary structures of CYP2A6 
(PDB 1Z10) and CYP2A13 (PDB 2P85) were determined by DSSP (55).  Boxes and double 
underline indicate α helices and β sheets, respectively.  Italics indicate N- and C-terminal 
modifications of CYP2A13 to create the truncated, His-tagged form used for expression, 
purification, and crystallization.  The substrate recognition sites are highlighted in grey. 
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Figure 1.7.  The active site of CYP2A13 (PDB 2P85) with indole in the active site 
(dark pink).  The ten residues mutated in this study are labeled and shown as sticks.  
Substrate recognition sites are SRS-1 (yellow), SRS-2 (orange), SRS-3 (green), SRS-
4 (cyan), SRS-5 (purple), and SRS-6 (pink).  The heme group is colored red.  Major 
helices are labeled.   
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Chapter 2. 
 
Methods and Procedures 
Introduction 
  Several of the methods used to compare CYP2A13 and CYP2A6 are common 
to multiple parts of this study.  To avoid redundancy, these methods and procedures 
are presented in this chapter and will be referenced throughout the rest of this thesis.  
The majority of these methods and procedures are well established in the cytochrome 
P450 field, although details in the purification and assay protocols have been 
optimized. 
  Methods and procedures necessary to the overall study, for example, protein 
engineering and site directed mutagenesis, which were not actually performed by me 
are described with a short description of the general method.  Purification of 
cytochrome b5, an accessory protein necessary for the phenacetin metabolism assay, 
is not described because a prior lab member purified this protein (1).   
Cytochrome P450 Modifications and Mutations 
Modifications: The CYP2A13 and CYP2A6 proteins were altered to form 
CYP2A13dH and CYP2A6dH, referred to CYP2A13 and CYP2A6 throughout.  The 
N-terminal transmembrane sequence (∆2-23) was truncated and four charged residues 
were added to the N-terminus in order to increase the expression yield and decrease 
the hydrophobic nature of the protein.  In addition, four histidine residues were added 
to the C-terminus to facilitate protein purification with a nickel affinity column (2).  
All of the CYP2A enzymes used in this study were truncated and histidine tagged. 
 28 
Mutations:  The mutations used in this study were made by swapping non-identical 
amino acids found in one CYP2A enzyme into the other.  For example, the CYP2A13 
mutations were produced using the modified CYP2A13 protein as a template and 
substituting the non-corresponding CYP2A6 residues. Multiple mutations were made 
additively, using a single or double mutant as the template.  All of the mutants were 
constructed using the QuikChange® kit (Stratagene, La Jolla, CA) (3).  The desired 
mutation is generated by annealing two synthetic oligonucleotide primers containing 
the desired mutation to opposite strands of the DNA vector (pKK2A13dH or 
pKK2A6dH) (4).  If possible, primers were designed with incorporation or deletion of 
a distinctive restriction site so the desired mutation could be easily detected by 
restriction digest analysis (Table 2.1).  Thermocycling was used to denature the DNA 
double stranded vector, anneal the primers to the DNA vector, and then to extend the 
primers (4).  This resulted in a double stranded mutant plasmid with staggered nicks.  
Methylated template and hemi methylated hybrid wild type/mutant DNA were 
destroyed with Dpn I endonuclease (4).  The mutant plasmid DNA was transformed 
into XL1-Blue supercompetent cells for nick repair and replication (4).  The presence 
of the mutation was identified by restriction digest followed by gel electrophoresis.  
Inclusion of the desired mutation and the absence of additional alterations in the 
mutated DNA were verified by DNA sequencing of the complete gene. 
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Cytochrome P450 Expression and Purification 
Transformation: Ampicillin resistant plasmids encoding the truncated, His-tagged 
variants of the cytochrome P450 enzymes were transformed into E. coli tetracycline 
resistant TOPP-3 cells (Stratagene, La Jolla, CA) (2).  The transformation was 
completed by incubating 100 µL of E. coli TOPP3 cells with 0.5 µL of the desired 
P450 plasmid (pKKP450dH) (~ 50 ng/mL) on ice for 30 minutes.  The cells were 
then heat shocked in a 42°C water bath for 30-45 seconds before the addition of 1.7 
µL of a 1:10 dilution of 100% β-mercaptoethanol (BME) and 1 mL of super optimal 
catabolite repressive (SOC) media.  Samples were incubated at 37°C for one hour 
while shaking at 250 rpm.  The samples were centrifuged at briefly to pellet the cells 
at 10,000 g.  All but 100 µL of the supernatant was removed.  The pellet was 
resuspended and plated on to Luria-Bertani media (LB) plates containing 1 µL of 50 
mg/mL ampicillin per 1 mL of agar and incubated overnight at 37°C. 
Expression:  One colony of transformed TOPP3/pKKP450dH was selected and used 
to grow a small-scale culture by inoculating a test tube containing 5 mL of LB media, 
5 µL of 50 mg/mL ampicillin, and 10 µL of 12.5 mg/mL tetracycline.  The culture 
was incubated at 37°C for 7-8 hours with shaking.  After incubation, a 200 mL 
medium-scale starter culture was inoculated with 50 µL from the 5 mL culture or a 
few cells from a glycerol stock (culture from the last expression stored at -80°C in a 
1:5 ratio with 100% glycerol) along with 200 µL of 50 mg/mL ampicillin and 400 µL 
of 12.5 mg/mL tetracycline.  The medium-scale starter cultures were grown overnight 
at 37°C with shaking at 250 rpm. 
 33 
  Eighteen one-liter flasks containing 250 mL of Terrific Broth (TB media with 
25 mL of TB salts) were each inoculated with 15 mL of the medium-scale overnight 
culture and 250 µL of 50 mg/mL ampicillin.  The cells were grown to an OD600 of 
between 1.0-1.5 at 37°C with shaking at 250 rpm.  Once the cells reached this 
absorbance, 20 mg aminolevulinic acid (ALA) and 60 mg isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to each 250 mL culture.  ALA is an 
essential component required to synthesize the heme porphyrin ring found in 
CYP450s.  IPTG was used to induce gene expression because it prevents the lac 
repressor from interfering with the transcription of the gene.  After the addition of 
ALA and IPTG, the incubation temperature was lowered to 30° C and the shaking to 
190 rpm.  Cells were grown for three days.  Once the incubation period was 
completed, cells were harvested by centrifugation at 6371 g for ten minutes.  Cell 
pellets were collected and stored at -80° C for later purification. 
Purification: The purification of cytochrome P450 enzymes began with the extraction 
of the protein from the whole bacteria cells.  The frozen cell pellet was thawed, and 
re-suspended with 200 mL of resuspension buffer (20 mM potassium phosphate 
buffer (KPi), pH 7.4, 20% glycerol).  Lysozyme (Sigma) was added to a final 
concentration of 0.3 mg/mL to initiate hydrolysis of peptidoglycan in the bacterial 
cell wall, and the solution was stirred at 4°C.  After 30 minutes, 200 mL of 4° C 
distilled water was added to the mixture in order to increase the hypotonic nature of 
the solution.  The mixture stirred for ten more minutes and was centrifuged at 8671 g 
for 15 minutes. After centrifugation, the cell pellet was flash frozen in a dry ice-
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ethanol slurry.  The pellet was resuspended in 100 mL of resuspension buffer (500 
mM KPi pH 7.4, 300 mM NaCl, 20% glycerol) and homogenized with a homogenizer 
on ice.  The suspension was sonicated on ice for three periods of 30 seconds.  The 
combined methods of flash freezing, homogenization, and sonication completed cell 
lysis. A second centrifugation at 8671 g removed cellular debris and the detergent 
Cymal-5 was added (at a final concentration of 4.8 mM) to solubilize the membrane-
bound CYP450s.  The solution was stirred at 4°C for approximately one hour to 
ensure maximal CYP450 solubility.  To separate the solubilized proteins from the 
other cell components, the solution was centrifuged at 70,000 g for one hour. 
The crude protein solution was purified using nickel nitrilotriacetic acid 
(NiNTA) metal affinity and carboxymethyl (CM) sepharose chromatography on a 
Fast Protein Liquid Chromatography system (FPLC).  The NiNTA column 
(QIAGEN) was able to significantly increase protein purity because of the four His 
residues engineered onto the carboxyl terminus (His-tag) of our P450 proteins.  The 
His-tag of the protein complexes with the Ni2+ bound to the NTA column matrix (5).  
The sample was loaded onto the NiNTA column at a 1 mL/min flow rate.  Non-
binding impurities were removed from the column with a two-column volume wash 
of loading buffer (100 mM KPi pH 7.4, 20% glycerol, 0.2 M NaCl, and 4.8 mM 
Cymal-5).  Proteins with weak affinity were washed off with a second wash 
additionally containing 8 mM histidine.  The His-tagged P450 proteins were eluted 
from the column by displacement with 80 mM histidine.  The sample was diluted 
five-fold with CM wash buffer (5 mM KPi pH 7.4, 1 mM EDTA, 20% glycerol, 4.8 
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mM Cymal-5) to reduce the salt concentration before loading on the ion exchange 
column.   
 The diluted protein was purified using ion exchange chromatography.  Protein 
was loaded onto a CM column, a cation exchanger (6).  Cytochrome P450 2A6 and 
2A13 both have a predicted isoelectric point of ~9.2 (ExPASy tools), which means 
that at the pH of 7.4, the protein will have a net positive charge.  After protein was 
bound to the negatively charged CM column, ten column volumes of CM wash buffer 
was used to remove impurities.  The protein was eluted from the column with a buffer 
containing salt (50 mM KPi pH 7.4, 1 mM EDTA, 20% glycerol, 0.5 M NaCl). 
 The purification was monitored throughout by comparing ~417/280 nm 
absorbance.  The final concentration of the protein was determined by both an 
absolute and CO difference spectra (7).  The protein was divided into aliquots and 
stored at -80°C. 
Rat NADPH Reductase Expression and Purification 
Expression: Cells were grown from a HMS174(DE3)/pETOR262 glycerol stock.  
Twenty five µL of the glycerol stock was inoculated into 100 µL of LB media with 
0.1 mL of kanamycin (50 mg/mL) in a 250 mL flask and grown overnight at 37° C 
with 250 rpm shaking.  The next morning, 0.5 mL of the freshly grown culture was 
inoculated into 250 mL of TB media, 25 mL of TB salts, and 0.25 mL of kanamycin 
(50 mg/mL).  A total of 12 flasks (3 Liters) were grown at 37° C at 250 rpm for four 
hours or until the OD550 absorption was greater than 0.8.  Then, IPTG (0.5 mM final 
concentration) was added to each flask.  After the addition of IPTG, cells were grown 
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at 30° C at 190 rpm for 48 hours.  Cells were harvested by centrifugation at 6371 g 
for 15 minutes at 4° C. 
Purification:  Thawed cells were resuspended in 150 mL of resuspension buffer (75 
mM Tris pH 8.0, 0.25 M sucrose, and 0.25 mM EDTA pH 8.0).  Lysozyme (3 mg) 
was added to the resuspended cells and the solution was stirred for 30 minutes at 4° C 
to initiate cell lysis.  The spheroplasts were pelleted by centrifugation at 4424 g at 4° 
C for 30 minutes.  The pellets were resuspended in 100 mL of affinity buffer (50 mM 
Tris pH 7.7, 0.1 mM EDTA pH 8.0, 0.05 mM DTT, 10% glycerol, and 0.1% triton X-
100).  The samples were hemolyzed with a tissue grinder and then sonicated for ten 
seconds ten times.  The mixture was stirred at 4° C for three hours.  The solution was 
centrifuged at 80,000 g for 45 minutes.   
The crude supernatant was purified by DE-52 anion exchange 
chromatography.  The DE-52 column was washed with 500 mL of affinity buffer at 
80-100 mL/min following sample loading.  Gradient elution was performed with 
1200 mL of affinity buffer with a concentration ranging from 0 – 350 mM KCl at a 
flow rate of 1 mL/min.  All of the yellow fractions were pooled and FMN added to a 
final concentration of 1 µM.   
 The pooled fractions were loaded at a flow rate of 0.16 mL/min onto a 2′5′-
ADP-Sepharose column equilibrated with 120 mL of affinity buffer.  The column was 
washed with 40 mL of affinity buffer at 0.2 mL/hr.  The sample was eluted with 10 
mL of 2 mM 2′AMP in affinity buffer at 0.16 mL/min.  All of the yellow fractions 
were pooled. 
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 The yellow fractions containing reductase were dialyzed (10 kDa molecular 
weight cutoff) against 2 liters of dialysis buffer (30 mM KPi pH 7.7, 20% glycerol, 
0.1 mM EDTA, and 0.002 mM FMN) for at least 8 hours.   
 The concentration of reductase present after dialysis was determined by a time 
course reaction measuring the amount of reductase required to catalyze the reduction 
of one micromole cytochrome c per minute. In a cuvette, 10 µL of cytochrome c (5 
mM, Sigma) and 2 µL of a 1:50 dilution of reductase from the dialysis were 
combined to a total volume of 990 µL. The reaction was initiated by the addition of 
10 µL of NADPH (10 mg/mL). The absorption at 550 nm was measured for five 
minutes.  The reductase concentration was determined in units/mL (Absorption 
change/minutes*Dillution factor) where 1 nmol of reductase is ~4 units.      
Carbon Monoxide Difference Assay (7) 
Instrument: UV-2101 UV/visible scanning spectrophotometer (Shimadzu Scientific 
Instruments, Inc., Columbia, MD) 
Procedure:  An unknown concentration of protein sample was diluted 1:9 into buffer 
to a total volume of 900 µL in a quartz cuvette.  A few crystals of dithionite were 
added to the cuvette and the cuvette was inverted before being placed into the 
spectrophotometer.  The sample was zeroed and then a baseline was taken from 500 - 
400 nm.  The sample was removed from the spectrophotometer and 50 bubbles of 
carbon monoxide added.  After the addition of carbon monoxide, the cuvette was 
inverted to mix and placed back in the spectrophotometer.  The sample was scanned 
from 500-400 nm.  Scans were taken every few minutes until the increase in 
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absorbance at 450 nm was maximal, as indicated by more than two scans at the same 
absorbance or a noticeable drop in absorbance. 
Analysis:  Concentration of P450 protein present was determined using Beer’s law: 
! 
c =
A
"l
 where c is concentration in µM, l is the pathlength (1 cm), A is absorption, and 
ε is the absorptivity coefficient which is equal to 0.091 µM-1cm-1. 
Ligand Binding Assay(7,8) 
Instrument: UV-2101 UV/visible scanning spectrophotometer (Shimadzu Scientific 
Instruments, Inc., Columbia, MD)  
Procedure:  Protein samples were diluted to a concentration of 1 µM in 100 mM 
potassium phosphate buffer (pH 7.4) and were divided equally between reference and 
sample 1 mL quartz cuvettes.  Concentrated ligand stocks were prepared in 100% 
ethanol.  The sample baseline was taken from 500 – 300 nm before beginning the 
titration.  Ligand was added to the sample cuvette, mixed, and allowed to equilibrate 
for 8 minutes.  An equal amount of solvent was added to the reference cuvette for 
every addition of ligand to the sample cuvette.  The total amount of solvent was less 
than 2% for each titration. After each ligand addition, a difference spectrum was 
recorded from 500 – 300 nm.  Additions were continued until there was no change in 
absorption band observed upon addition of ligand. 
Analysis:  Graphpad Prism 4 (Graphpad Software, San Diego, CA) is used to 
determine the Kd and ∆Amax with nonlinear least-squares regression fitting to the 
equation: 
! 
"A =
"A
max
2P
[P + S + K
s
# (P + S + K
s
)
2
# 4PS ] . 
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Phenacetin Metabolism Assay 
Instrument: Prominence HPLC System (Shimadzu Scientific Instruments, Inc., 
Columbia, MD) 
Reconstitution of Enzymes: CYP2A13, CYP2A6, and mutant enzymes were 
reconstituted with rat NADPH reductase (purified as described previously) and 
cytochrome b5 (purified by Brian Smith, a previous lab member) for 20 minutes at 
room temperature before use.  A 1:6:2 ratio of CYP450 enzymes to reductase to 
cytochrome b5 was used for all metabolism experiments since this ratio gave optimal 
metabolism (data not shown).   
Phenacetin O-Deethylation: Reconstituted protein system (30 pmol CYP450) was 
added to 100 mM potassium phosphate buffer (pH 7.4) with 0 – 250 µM phenacetin 
to total volume of 300 µL.  Phenacetin O-deethylation activity was determined using 
a phenacetin concentration of 250 µM and a final NADPH  (Sigma) concentration of 
500 µM.  The reactions were initiated with the addition of 30 µL of NADPH followed 
by incubation in a water bath at 37ºC for 30 minutes.  Reactions were terminated with 
15 µL 60% perchloric acid, denaturing all the enzymes present.  Samples were 
centrifuged for five minutes at 4300 g to remove precipitated protein and the 
supernatant was retained for analysis by HPLC.  HPLC analysis was completed using 
a 4.6 x 250 mm Phenomenex Luna C18 column with a flow rate of 1 mL/min and an 
isocratic mobile phase consisting of 8% acetonitrile with 50 mM potassium phosphate 
solution (pH 4.9).  Acetaminophen standards were prepared in the same manner as 
the samples except for the absence of the reconstituted protein system.  The lack of 
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reconstituted protein system did not affect the standard curve as indicated by 
preliminary experiments (data not shown). 
Analysis:  Graphpad Prism 4 (Graphpad Software, San Diego, CA) was used to 
determine the Km and kcat with nonlinear least-squares regression fitting to the 
equation: 
! 
Activity =
kcat
2P
[P + S + Km " (P + S + Km )
2
" 4PS ]. 
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Chapter 3. 
Ligand Binding Studies 
Introduction 
 Ligand binding studies have been utilized to study P450s since the 1960s (1-
3).  Schenkman et al. noted that the addition of various ligands into a cuvette 
containing liver microsomes resulted in spectral changes (2).  Three distinct types of 
spectral changes are recognized: type I, type II, and reverse type I (Figure 3.1) (1,2).   
Type I spectra are identified by the formation of a peak at ~385 nm when a 
substrate is bound and a trough at ~420 nm (Figure 3.1, Panel A).  The majority of 
type I spectra shifts are the result of substrate binding.  This type of spectral change 
reflects a shift from low-spin, 6-coordinate iron state when a water molecule is bound 
to the iron to high-spin, 5-coordinate iron when a ligand binds to the active site of the 
protein, displacing the water molecule (1,4).  
Reverse type I spectra have a peak formation at ~420 nm and a trough at ~385 
nm (Figure 3.1, Panel B) (1).  Ligands causing reverse I spectra may bind in such a 
way as to increase the water coordination to the heme iron or they may bind at a 
different location in the active site than type I ligands (5).  Typical reverse type I 
ligands are hard to characterize because a reverse type I ligand may shift spectra at 
higher ligand concentrations or may not be a reverse type I when bound to a different 
CYP450.  Phenacetin is frequently mentioned as a reverse type I binder in early 
literature, although it is also reported as causing a type I spectral shift (5).  
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   The third category of spectral binding shift is the type II, characterized by a 
peak at ~425-435 nm and a broad trough at 390-410 nm (Figure 3.1, Panel C).  Type 
II ligands are generally nitrogen-containing inhibitors that can replace the water 
molecule bound to the heme iron, thus stabilizing a low-spin, 6-coordinate iron.   
In this study, we utilized spectral binding shifts to survey a series of four 
structurally diverse cytochrome P450 2A ligands and determine the binding affinities 
for both CYP2A6 and CYP2A13 enzymes.  These four ligands were coumarin, 2'-
methoxyacetophenone (MAP), phenethyl isothiocyanate (PEITC), and phenacetin.  
Additionally, ten active site residues that differ between CYP2A13 and CYP2A6 
were systematically examined for their contributions to ligand binding.  These ligand 
binding studies identified a number of substitutions that changed the KD significantly 
for one or more substrates.  This allowed us to determine if all four ligands interact 
with the same amino acid residues.  
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Figure 3.1.  The three types of spectral binding spectra are illustrated above.  A.  
Type I spectra of phenacetin binding to CYP2A13.  B.  Reverse Type I spectra of 
agroclavine binding to rat liver microsomes, based on figure 1 from Jefcoate (1).  C.  
Type II spectra of pilocarpine binding to CYP2A6 I208S/I300F/G301A/S369G. 
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Methods 
 All proteins used in this chapter were expressed and purified according to the 
protocols found in chapter 2.  The procedure for the spectral ligand binding assay is 
also found in chapter 2. 
Results 
Binding of structurally diverse ligands to CYP2A6 and CYP2A13 wild type proteins: 
The 2A ligands coumarin, 2'-methoxyacetophenone (MAP), phenethyl isothiocyanate 
(PEITC), and phenacetin all displayed type I binding spectra with a shift from ~420 
nm to ~385 nm (Figure 3.1, Panal A).  All of the ligands surveyed bound more tightly 
to CYP2A13 than to CYP2A6 (Table 3.1).  The ligand with the largest difference in 
binding affinity is phenacetin, which binds with a KD of ~34 µM for CYP2A13 but 
does not cause a spectral shift in CYP2A6 at 250 µM phenacetin.  The ligand MAP 
had the second largest difference in binding affinity, it binds 87-fold more tightly to 
CYP2A13 than to CYP2A6.  CYP2A13 has an affinity of 0.85 µM for this ligand, 
while the KD for CYP2A6 is 74 µM.  The inhibitor PEITC bound to CYP2A13 14-
fold more tightly than to CYP2A6 with KD values in the sub-micromolar range for 
2A13 and low micromolar range for CYP2A6.  In contrast to these three ligands, the 
binding affinity of both CYP2A enzymes appeared to be very similar for coumarin 
with KD values ~3 µM. 
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Table 3.1.  Binding constants for various ligands to cytochrome 2A6 vs. cytochrome 2A13.  
Values are in parenthesis indicate individual trials, value below is the average of the duplicate 
measurements.  A third trial was preformed in some cases.  All trials had R2 goodness of fit 
values >0.99.  
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O
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O
N
H
O
 
N.D. 
(30, 35, 
37) 
 34. 
N.D. 
 
N.D. - KD not determined due to little or no spectra shift. 
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Ligand binding to mutants of CYP2A13:  After determining dissociation constants for 
both CYP2A13 and CYP2A6 wild type enzymes, we proceeded to characterize the 
ten CYP2A13 proteins into which single active site residues from CYP2A6 were 
substituted.  As with the wild type enzymes, the most pronounced differences in 
binding affinity were with phenacetin as the ligand (Table 3.2).  The wild type 
CYP2A13 had a KD value of 34 µM (Figure 3.2, panel A), while a binding constant 
could not be determined for CYP2A6 (Figure 3.2, panel B).  Two CYP2A13 mutants, 
F300I and A301G, reduced phenacetin binding to the point where a KD value could 
not be determined (Figure 3.2, Panel C).  More than a three-fold decrease in 
phenacetin affinity resulted with the mutation of residues 365, 369, and 208 (Figure 
3.3).  The substitution of Ile for Leu366 led to the only mutant with a substantial 
increase in binding affinity with a KD of ~2 µM (Table 3.2).  All other mutations had 
little affect on phenacetin ligand binding affinity. 
MAP binding to the CYP2A13 mutants revealed that four modifications 
resulted in substantially different KD values compared to the wild type CYP2A13 
enzyme.  Substitution of isoleucine for phenylalanine 300 (F300I) resulted in a >17-
fold increase in KD to 15 µM, from the wild type affinity of 0.85 µM (Figure 3.3).  
S208I had a 14-fold increase to 12 µM.  A301G was characterized as binding MAP 
with a KD of 8.2 µM, a decrease in affinity of more than 9-fold (Figure 3.3).  A117V 
had a more moderate 4.8-fold decrease in affinity for MAP.  The remaining six 
mutations had relatively little effect on MAP binding, although L366I slightly 
improved binding affinity (0.56 µM).
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Figure 3.2.  Ligand binding titration spectra 
with phenacetin as the ligand, increasing 
concentrations of ligand indicated from red (~1 
µM) to purple (250 µM).  A.  CYP2A13 with 
phenacetin.  B.  CYP2A6 has no noticeable 
shift up to concentration of 250 µM when 
phenacetin is used as a ligand.  C.  The mutant 
CYP2A13 A301G has a very little spectra 
shift. 
 
  
 
 
 
 
 
 
 
 
A. B. 
C. 
 49 
 
 
 
N.D. - KD not determined due to little or no spectra shift. 
Enzymes 
MAP KD  
(µM) 
PEITC KD  
(µM) 
Coumarin KD  
(µM) 
Phenacetin KD  
(µM) 
2A6 (65, 69, 104) 
74.0 
(5.4, 6.9)  
6.2 
(2.7, 3.4)  
3.1 N.D. 
2A13 (1.0, 0.66) 
0.85 
(0.31, 0.54) 
0.43 
(2.0, 3.3)  
2.7 
(30, 35, 37) 
34. 
2A13 Mutants:        
   L110V 
 1.6 
(0.43, 0.48) 
0.46   1.7 18. 
   A117V (3.7, 4.6)  
4.1 1.2   1.8 20. 
   S208I (13, 11)  
12. 
(0.99, 1.7) 
1.4 
(8.0, 7.9) 
 7.9 110. 
   A213S 
 2.9 0.87   3.4 65. 
   F300I (16, 14)  
15. 
(6.2, 5.8)  
6.0 
(14.1, 13.1) 
14. N.D. 
   A301G   (8.3, 8.0) 
8.2 
(2.0, 4.0)  
3.1   4.2 N.D. 
   M365V 
 1.7 
(1.6, 1.8)  
1.7 
 (4.4, 5.6) 
5.0 130. 
   L366I 
 0.56 0.34 
(0.35, 0.80) 
0.57 2.3 
   G369S 
 1.6 
(1.8, 1.8) 
1.8 
(5.5, 6.6) 
6.0 97. 
   H372R 
 0.77 1.0 1.5 20. 
Table 3.2.  KD values for wild type CYP2A enzymes and the ten CYP2A13 mutants.  All 
trials represent the mean of duplicate trials (values from individual trials in parenthesis) for 
wild type enzymes and for all mutants with a greater than 3-fold difference in KD from wild 
type CYP2A13.  The KD of the mutant CYP2A13 enzymes with phenacetin were only done 
once, these results are preliminary. 
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Figure 3.3.  Fold-difference (KD of Mutant/KD of CYP2A13) of the ten CYP2A13 
mutants compared to wild type CYP2A13 and CYP2A6. 
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Binding of PEITC to wild type CYP2A13 was characterized by a KD of 0.43 
µM, approximately 14-fold higher affinity than CYP2A6 (KD 6.2 µM) (Figure 3.3).  
The single substitution of F300I in the CYP2A13 protein resulted in a 14-fold loss in 
PEITC affinity, such that its KD (6.0 µM) is essentially that of CYP2A6 wild type.  
The mutation A301G, located directly adjacent to F300I, demonstrated a 7-fold 
increase in KD to 3.1 µM.  The mutants A117V, S208I, M365V, and G369S had KD 
values that were increased 3 to 4-fold compared to the wild type CYP2A13.   The 
remaining single mutants yielded smaller changes in the PEITC binding affinity.  The 
substitution L366I was the only protein to demonstrate an increase in binding affinity 
for PEITC, though the change was small. 
 In contrast to PEITC and MAP, which bind more tightly to CYP2A13 than 
CYP2A6, the KD value for coumarin is ~2.9 µM for both CYP2A13 and CYP2A6.  
Again, the F300I substitution had the most dramatic effect on KD, with a 5-fold 
increase to 14 µM.    Two other substitutions, G369S and S208I, increased KD values 
by 2- and 3-fold to 6.0 µM and 7.9 µM, respectively.  The substitution H372R 
increased coumarin binding affinity by nearly 50% to a KD of 1.5 µM, while L366I 
increased coumarin binding affinity by 5-fold to 0.57 µM. 
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Discussion 
The goal of our present study was to understand the differences in structure-
function relationships between the human cytochrome CYP2A6 and CYP2A13 
enzymes and their ligands and to identify individual amino acid residues that mediate 
those binding affinities.  Initially a series of four structurally diverse cytochrome 
P450 2A ligands were surveyed and binding affinities determined for both CYP2A6 
and CYP2A13 enzymes.  Coumarin was chosen because it is an often-used marker 
substrate for cytochromes P450 in the 2A subfamily (6-8).  2'-methoxyacetophenone 
(MAP) (9,10) is also a CYP2A substrate, while phenethyl isothiocyanate (PEITC) is 
an inhibitor (11).  Phenacetin was selected as a ligand because it is a differential 
substrate of CYP2A13 but not CYP2A6 (12).  Examination of these structurally 
diverse cytochrome P450 2A ligands revealed a very large range in the affinities of 
CYP2A13 vs. CYP2A6.  At the extremes, coumarin bound equally well to both 
proteins, while phenacetin bound to CYP2A13 but did not cause a spectral shift in 
CYP2A6 (Table 3.1).   
A structure of CYP2A6 has been determined with the strictly planar coumarin 
compound in the active site (13).  This structure shows that the coumarin ketone 
oxygen hydrogen bonds with N297 within the largely planar active site and positions 
C7 for hydroxylation.  Indeed, 7-hydroxycoumarin in the only metabolite detected for 
CYP2A6.  Both the hydrogen bonding residue and the planarity of the active site are 
conserved in the 2A13 structure (13).  These structural similarities, the nearly 
identical KD values, and the formation of the 7-hydroxycoumarin metabolite by both 
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proteins suggest that coumarin would bind similarly in CYP2A13.  However, 
Weymarn and Murphy observed that while 7-hydroxycoumarin is the major coumarin 
metabolite (43%) for CYP2A13, a significant amount of the 3,4 epoxide is also 
observed (30%), as well as smaller amounts of 6-hydroxy- and 8-hydroxycoumarin 
(14).  In side-by-side studies, none of these products were observed for CYP2A6.  
This suggests that, despite the nearly identical KD values, that in CYP2A13, coumarin 
1) binds by hydrogen-bonding with N297, but is less constrained in its approach to 
the activated oxygen on the heme so that the C6 and C8 on either side of C7 can also 
be hydroxylated and 2) also binds in a second, inverted orientation to expose the 
C3/C4 carbons for formation of the epoxide. 
MAP binding showed a large difference between CYP2A13 (KD 0.85 µM) 
and CYP2A6 (KD 74 µM).  Enzymatically MAP is O-demethylated by both enzymes 
to produce 2'-hydroxyacetophenone and formaldehyde.  Although kinetics are not 
available for MAP metabolism, Su et al. reported that at 1 mM substrate 
concentration, CYP2A13 metabolized MAP at a rate 4-fold faster than CYP2A6 (15).  
Thus, the substantial differences in MAP affinity were not expected based on the 
single productive orientation in the active site indicated by a single product and the 
preliminary metabolic rate information available.   
The inhibitor PEITC had a 14-fold greater affinity for CYP2A13 compared to 
CYP2A6.  PEITC can inhibit without enzymatic activation, but appears to also 
inactivate via covalent modification of the CYP2A6 and CYP2A13 proteins (11).  
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The KI values for inhibition of CYP2A13 with PEITC is 10-fold lower than for 
CYP2A6.  
Phenacetin was selected as a ligand because Fukami et al. determined 
CYP2A13 metabolizes phenacetin to acetaminophen while CYP2A6 had very low 
activity (12).  CYP2A13 metabolized phenacetin O-deethylation with higher activity 
than CYP1A2, the cytochrome P450 commonly attributed to phenacetin metabolism.  
CYP2A13 had a binding affinity for phenacetin of 34 µM, while the binding affinity 
of CYP2A6 could not be determined as no discernable spectra shift was evident at the 
highest concentration tested (250 µM phenacetin). 
To determine the amino acids responsible for such disparate ligand KD values, 
active site residues that differ between CYP2A13 and CYP2A6 were systematically 
examined for their contributions to ligand binding.  Ten positions were selected for 
examination in this study because they either line the CYP2A13 active site or are 
immediately adjacent to residues that do (Chapter 2) (16).  The resulting engineered 
CYP2A13 proteins were characterized using ligand binding titrations with 
phenacetin, MAP, PEITC, and coumarin.  
A single mutation, phenylalanine to isoleucine, at the first shell active site 
position (300), yielded 5- to >17-fold decreases in the binding affinity for the four 
cytochrome P450 2A13 ligands examined.  The loss in binding affinity for phenacetin 
was so substantial that binding affinity could not be determined (Table 3.2). Despite 
the ligand structural diversity, phenacetin, MAP, PEITC, and coumarin binding were 
all significantly perturbed by this single substitution.  This indicates that this 
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phenylalanine plays a central role in the active site.  Comparison of the CYP2A6 and 
CYP2A13 structures reveals that I300 and F300 overlap at the alpha carbon atom, but 
that the phenyl ring is rotated farther away from the bound ligand than the isoleucine 
side chain (Figure 1.4) (13,16).  However, the two proteins were crystallized with 
different ligands, which could affect the side chain positioning.  No data is presently 
available regarding the effects of this mutation on metabolism of the substrates 
examined here, although Guengerich and coworkers (17) found that both the residues 
at positions 300 and 297 were critical for CYP2A6 metabolism of indole.  Overall, it 
is clear that this residue is critical for the higher affinity of CYP2A13 with all four 
ligands in this study.   
Substitution of the adjacent CYP2A13 residue, A301, to glycine removes the 
side chain and caused spectral sifts that were so diminished with phenacetin that a KD 
could not be determined.  The CYP2A13 A301G mutation also had a 7- to 9-fold 
increase in the KD for MAP and PEITC, respectively, but does not significantly alter 
the KD for coumarin (Figure 3.3).  This suggests that coumarin interacts differently 
with the residue at position 301 than does phenacetin, MAP, or PEITC.  Since MAP 
and PEITC bind more tightly to CYP2A13, interactions with this residue may 
contribute to ligand selectivity.  Again, there are no data available to determine the 
effects of this substitution on substrate metabolism. 
The S208I substitution has a 14-fold increase in the KD for MAP, but much 
smaller ~3-fold effects on phenacetin, PEITC, and coumarin binding (Figure 3.3). 
The more moderate effects on coumarin binding are consistent with the results of He 
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et al., who showed that this mutation had little effect on the kinetics of coumarin 7-
hydroxylation by CYP2A13 (8).  Of note, this mutation is reported to decrease the 
catalytic efficiency of CYP2A13 NNK metabolism to both the keto aldehyde and keto 
alcohol products, neither of which are formed efficiently by CYP2A6 (18).  The 
CYP2A13 wild type structure shows that S208 forms part of the C-terminus of the F 
helix (Figure 1.4).  Several bacterial and mammalian cytochrome P450 structures 
have indicated that the N-terminus of the F helix can be fairly mobile and may form 
part of the small molecule entrance/exit channel (19-21).  Thus the position of this 
residue could change depending on both the position and the identity of the ligand. 
Substitutions of A117V, M365V, and G369S had more moderate effects on 
binding affinity for one or two substrates (Figure 3.3).  A117V yielded a 4.8-fold 
increase in MAP KD, but much smaller changes for phenacetin, PEITC, or coumarin.  
Although this mutation was not reported to significantly alter the Km for coumarin 
metabolism, mutation did substantially alter the kcat, such that this single mutation 
interconverted the CYP2A13 kcat for coumarin (0.31 µM-1min-1) and CYP2A6 (2.6 
µM-1min-1) (8).  Similarly, CYP2A13 A117V altered the catalytic efficiency of NNK 
metabolism by alterations in the Vmax, but not the Km (18).  These results suggest that 
for some ligands like MAP, the residue at position 117 has a moderate influence on 
binding affinity.  While, for other ligands like coumarin residue 117 is more critical in 
the difference in metabolic rates than the difference in binding affinities for the two 
enzymes.  In a similar manner, substitution of M365V and G369S altered the 
affinities for PEITC and phenacetin, but had much smaller effects on MAP and 
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coumarin binding.  This is in agreement with the CYP2A13 structure that shows 
A117, M365 and G369 located more peripherally to the indole ligand in the 
CYP2A13 binding cavity while F300 and A301 are both centrally located and likely 
to cause a change in binding regardless of the ligand (Figure 1.4) (16). 
 The L366I mutation was the only change to increase binding affinity for 
ligands (Figure 3.3).  The KD for phenacetin was reduced 93% from 34 µM to 2.3 µM 
and coumarin was reduced 80% from 2.7 µM to 0.57 µM.  The reductions for PEITC 
and MAP were smaller.  Thus, the substitution of the leucine found in CYP2A13 for 
the valine in CYP2A6 must result in an active site that is able to better accommodate 
a variety of ligands. 
 Finally, the H372R substitution is notable because, although this mutation is 
reported to have significant effects on the kcat for coumarin and thus the catalytic 
efficiency (22), no significant changes were observed in KD for coumarin, MAP, 
PEITC, and phenacetin.  A separate report indicated that this mutation caused very 
large alterations in the Km for NNK metabolism to the keto aldehyde product and 
eliminated the keto alcohol metabolite (18).  Therefore, this residue may be relevant 
to NNK binding, but not the ligands examined in this study.  It is also possible that 
the H372R mutation may not have a direct effect on ligand binding, but is capable of 
altering metabolism through a different means. 
The goal of this study was to gain insight into the differences in structure-
function relationships between the human cytochrome CYP2A6 and CYP2A13 
enzymes and their ligands.  Binding titrations of chemically diverse ligands to 
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CYP2A13 and CYP2A6 were used in conjunction with site-directed mutagenesis to 
identify key active site amino acids.  Overall, the experimental spectral titrations 
identify F300I as the most important amino acid difference between CYP2A13 and 
CYP2A6.  F300I altered binding of coumarin, MAP, PEITC, and phenacetin.  A301G 
altered MAP, PEITC, and phenacetin binding, while S208I altered MAP and 
phenacetin binding.  Mutations at positions 117, 365, 366, and 369 had smaller 
effects on the binding affinities of one or two substrates.   
Conclusion 
In conclusion, residues at positions 300, 301, and 208 appear to be the most 
critical in the determining the selectivity of ligand binding, while 117, 365, and 369 
have smaller effects.  Mutation of the residue 366 increased the binding affinity for 
all ligands. The other positions examined, 110, 213, and 372 yielded KD values that 
were relatively little changed by comparison with wild type CYP2A13.  These ligand 
binding assays provide a greater understanding of CYP2A active site structure 
activity relationships. 
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Chapter 4 
Metabolism Assay with Phenacetin as a Substrate 
Introduction 
 In the previous chapter, ligand binding studies identified several CYP2A13 
residues the mutation of which resulted in significant changes in ligand binding 
affinity for MAP, PEITC, coumarin, and phenacetin.  Since binding affinity does not 
always correlate directly to altered substrate metabolism, the next phase in the project 
was to determine whether the same amino acids also alter substrate metabolism.  
Phenacetin was selected as the substrate used to probe for residues contributing to the 
metabolic differences between CYP2A13 and CYP2A6 because we observed the 
largest difference in CYP2A ligand binding with phenacetin. 
 The primary metabolite of phenacetin is acetaminophen via O-deethylation, 
the commonly used analgesic and antipyretic (Scheme 4.1, panel A and B).  
Phenacetin was used as an analgesic and antipyretic, both alone and in combination 
with aspirin and caffeine, between 1887 and 1983 (1).  After 1983, phenacetin was 
removed from market because of implications in human nephropathy (2).  Phenacetin 
has also been implicated in the development of tumors in the urinary tract and nasal 
cavity of rats (3,4).  Due to its connection with cancer and nephropathy, the 
metabolism of phenacetin has been studied extensively.  Phenacetin is also N-
deacetylated to the toxic metabolite p-phenetidine and hydroxylated to form an acetol 
metabolite (Scheme 4.1, panel A) (5-7).  Enzymes from the cytochrome P450 1A 
family have previously  
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Scheme 4.1.  A.  Phenacetin is metabolized by several cytochrome P450s.  The major 
product is acetaminophen via O-deethylation.  p-Phenetidine and an acetol secondary 
metabolite have also been identified as P450 metabolites in previous.  B. The 
phenacetin O-deethylation reaction as catalyzed by cytochrome P450 enzymes.  1) A 
hydrogen atom is abstracted from the subterminal alkyl carbon by activated oxygen of 
the cytochrome P450.  2) The hydroxyl group on the heme iron is then transferred to 
the sub-terminal carbon that had the hydrogen abstracted.  3)  Rearrangement occurs 
leading to the formation of acetaminophen and acetyl aldehyde. 
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been identified as the major enzymes responsible for phenacetin O-deethylation to 
acetaminophen (5,8,9).  Other cytochrome P450s such as CYP2C9, CYP2A19, and 
CYP2E1 have also been reported to metabolize phenacetin, although with much 
higher Km values than CYP1A2 (9-11). 
Fukami and coworkers recently established that CYP2A13 catalyzes 
phenacetin O-deethylation with an even higher kcat (2.9 ± 0.3 pmol/min/pmol) and a 
lower Km (21.8 µM) than CYP1A2 (1.9 ± 0.1 pmol/min/pmol and 29.2 µM, 
respectively) (12).  In contrast, CYP2A6 has been reported to have a very high Km 
(4000 µM) for phenacetin O-deethylation (9-11).  Our own spectral binding analysis 
determined that CYP2A13 binds phenacetin with a KD of ~34 µM, while CYP2A6 
does not cause a spectral shift.  The efficient metabolism of phenacetin by CYP2A13 
and poor metabolism by CYP2A6 made phenacetin an ideal metabolite to identify 
amino acids responsible for differential substrate recognition in the CYP2A enzymes. 
We hypothesized that the amino acids identified with roles in phenacetin 
binding would also be involved in differential phenacetin metabolism.  The same ten 
mutants used in the spectral ligand binding study were tested for their ability to 
catalyze phenacetin O-deethylation compared to both wild type CYP2A13 and 
CYP2A6 enzymes.  Since it is often easier to destroy enzyme activity than to create 
enzyme functionality where none existed previously, we verified the importance of 
these amino acids to phenacetin metabolism by introducing the CYP2A13 amino 
acids at these positions into CYP2A6.  Because CYP2A13’s ability to metabolize 
phenacetin is likely the cumulative result of a number of substitutions, we also 
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constructed CYP2A6 mutants using combinations of CYP2A13 mutants that reduced 
the phenacetin O-deethylation metabolism the most.  
Methods 
 All proteins used in this chapter were expressed and purified according to the 
protocol found in chapter 2.  The procedure for the phenacetin metabolism assay is 
also found in chapter 2.  When full length CYP450 was assayed, the method was 
slightly modified.  In order to stabilize the full length CYP450 enzyme the lipid 
dilauroylphosphatidylcholine (DLPC) was added to the reconstituted protein system 
in addition to NADPH cytochrome P450 reductase, cytochrome b5, and P450 protein. 
 We determined the lower limit of detection for the phenacetin metabolism 
assay to be 0.026 pmol/min/pmol.  The lower limit of detection was determined by 
the mean of 12 sample blanks (no acetaminophen present in sample) multipled by two 
times the standard deviation of those samples.  Kinetic parameters were determined 
with a range of (0.5 – 250 µM phenacetin) for all proteins with a phenacetin O-
deethylation activity greater than 0.7 pmol/min/pmol in the 250 µM activity studies. 
Results 
Comparison of CYP2A13 single mutations at 250 µM Phenacetin:  The phenacetin O-
deethylation activity was determined at 250 µM for all ten CYP2A13 mutants and for 
CYP2A13 and CYP2A6.  The activity of CYP2A13 was ~3.4 pmol/min/pmol (Table 
4.1).  In contrast, the activity of CYP2A6 was barely above our lower limit of 
detection at 0.08 pmol/min/pmol.   
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 Two mutants, A117V and L366I, resulted in five-fold and three-fold increases 
in activity, respectively.  However, the other eight mutations resulted in decreases in 
phenacetin O-deethylation (Figure 4.1).  The single mutations L110V, S208I, F300I, 
A301G, M365V, and G369S all resulted in phenacetin metabolism that is less than 
15% of the wild type CYP2A13 activity.  The residues at position 300, 301, 208, and 
369 had the largest reductions in activity.  The A213S and H372R mutations had a 
less pronounced decrease in activity with rates around ~1 pmol/min/pmol. 
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Protein 
Rate of product formation 
 (pmol/min/pmol)a 
! 
ActivityMu tan t
ActivityCYP 2A13
 
CYP2A13 3.4 ± 0.6 1.0 
   L110V 0.40 ± 0.07b 0.1 
   A117V 18 ± 2 b 5 
   S208I 0.35 ± 0.06 b 0.1 
   A213S 1.5 ± 0.5 b 0.4 
   F300I 0.07 ±0.01 b 0.02 
   A301G 0.18 ± 0.03 b 0.05 
   M365V 0.5 ± 0.1 b 0.1 
   L366I 11 ± 1 b 3 
   G369S 0.4 ± 0.1 b 0.1 
   H372R 1.06 ± 0.04 b 0.3 
aData represent the average of two independent experiments each conducted in triplicate. 
bStatistically significant differences were calculated using a t test for the rate of product 
formation with wild type CYP2A13 versus mutant rate of product formation and are indicated 
with asterisks (*,p < 0.0001). 
 
 
 
 
 
Table 4.1.  Phenacetin O-deethylation rates and comparisons for CYP2A13, and 
CYP2A13 mutants.  All assays used 250 µM phenacetin.  
 
 67 
 
0
5
10
15
20
2A13 Mutants
 
 
 
 
 
 
 
 
 
Figure 4.1.  Effects of single mutations on CYP2A13 phenacetin O-
deethylation rates. 
 68 
Comparison of CYP2A6 mutations at 250 µM Phenacetin:  The majority of CYP2A6 
single mutants had very little phenacetin O-deethylation activity with the exception of 
V110L, I300F, and S369G, which had a slightly increased phenacetin O-deethylation 
activity of (0.2-0.3 pmol/min/pmol) (Table 4.2).  This suggested that phenacetin O-
deethylation activity in the CYP2A family was the aggregate result of several amino 
acid substitutions between CYP2A13 and CYP2A6.   
Several CYP2A6 multiple mutants were constructed to explore this 
hypothesis.  The double mutant CYP2A6 V365M/I366L was generated because of the 
unique placement of these two substitutions and the opposite effect observed at these 
positions with the CYP2A13 single mutants.  However, this double mutant had 
activity similar to wild type CYP2A6.  The double mutant CYP2A6 I300F/G301A 
showed a moderate increase in activity to 0.63 pmol/min/pmol (Table 4.2).  The 
addition of I208S or S369G substitutions to the I300F/G301A mutant led to further 
increases in activity: 0.8 pmol/min/pmol and 1.0 pmol/min/pmol, respectively (Table 
4.2).    The inclusion of all four mutations (2A6dH I208S/I300F/G301A/S369G) led 
to a mutant with activity of ~3 pmol/min/pmol, similar to the activity of CYP2A13.  
The additive effects of these mutations can be easily visualized in Figure 4.2.  
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Table 4.2.  Phenacetin O-deethylation rates by CYP2A6 and CYP2A6 mutants.  All 
assays used 250 µM phenacetin. 
 
 
aData represent the average of two independent experiments each conducted in triplicate. 
bValue below the detection limit of our system (0.026 pmol/min/pmol). 
cNot applicable. 
dStatistically significant differences were calculated using a t test for the rate of product 
formation with wild type CYP2A6 versus mutant rate of product formation (p < 0.05). 
eStatistically significant differences were calculated by t test for the rate of product formation 
with wild type CYP2A6 versus mutant rate of product formation (p < 0.0001). 
 
Protein 
Rate of product formation 
(pmol/min/pmol)a 
! 
Activity
ActivityCYP 2A 6
 
2A6 0.08 ± 0.04 1.00 
   V110L 0.3 ± 0.1d 3.9 
   V117A < det. lim.b N.A.c 
   I208S < det. lim.b N.A.c 
   S213A 0.08 ± 0.00  1.0 
   I300F 0.21 ± 0.04d  2.7 
   G301A 0.07 ± 0.01  0.8 
   V365M 0.13 ± 0.03d  1.7 
   I366L < det. lim.b N.A.c 
   S369G 0.21 ± 0.05d  2.6 
   R372H 0.14 ± 0.09  1.7 
   V365M/I366L 0.12 ± 0.04 1.5 
   I300F/G301A 0.63 ± 0.09 e 7.9 
   I208S/I300F/G301A 0.8 ± 0.1 e 10 
  I300F/G301A/S369G 1.02 ± 0.09 e 13 
I208S/I300F/G301A/S369G 3.0 ± 0.3 e 38 
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Figure 4.2.  Effects of CYP2A6 mutations on phenacetin O-
deethylation rates (250 µM phenacetin). 
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Phenacetin O-deethylation Kinetic Parameters:  The kinetic parameters between 
CYP2A13 mutant enzymes varied considerably (Table 4.3).  As expected, CYP2A13 
A117V and L366I mutations that caused increased activity at 250 µM phenacetin also 
had increased kcat values (Figure 4.3, panel A).  However, the Km for A117V and 
L366I were also both increased compared to wild type CYP2A13 (Table 4.3).  This 
resulted in the mutant A117V having a catalytic efficiency 1.5-fold greater than 
CYP2A13 while the L366I mutation had a catalytic efficiency identical to CYP2A13 
(Table 4.3).  Three other CYP2A13 mutants, A213S, M365V, and H372R had kcat 
values below that of wild type CYP2A13 (Figure 4.3, panel B).  One of these 
mutations, H372R, had a Km value significantly decreased to ~5 µM; however, a 
corresponding decrease in kcat value resulted in catalytic efficiency identical to 
CYP2A13 (Table 4.3).  
 Each of the CYP2A6 single mutants had activities at 250 µM phenacetin that 
were too low to determine reliable kinetic parameters.  However, several of the 
CYP2A6 multiple mutants had sufficient activity to determine kinetic parameters 
(Table 4.3).  The CYP2A6 triple mutants I208S/I300F/G301 and 
I300F/G301A/S369G both had kcat values of ~0.9 pmol/min/pmol, significantly 
increased from CYP2A6, and equivalent to several of the CYP2A13 single mutants 
(Figure 4.3, panel C).  In contrast, the Km value of the triple mutant CYP2A6 
I300F/G301A/S369G was 4.9 µM, or half that of CYP2A13, while the triple mutant 
CYP2A6 I208S/I300F/G301A had a Km of 39 µM, a four-fold increase from 
CYP2A13. 
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aData represent the average of two independent experiments each with all concentrations 
conducted in triplicate. 
bThis is the full length enzyme.  
cN.D., Reliable kinetic values could not be determined for enzymes with activities <0.7 
pmol/min/mol at 250 µM phenacetin (see Tables 2 and 3) 
dStatistically significant differences were calculated using a t test for the Km and kcat of wild 
type CYP2A13 versus the mutant kinetic parameters (p < 0.001). 
 
 
 
 
 
 
 
Enzyme Km 
(µM) 
kcat 
(min-1) 
kcat/Km 
(µM-1min-1) 
! 
k
cat
/K
m( )Mu tan t
(k
cat
/K
m
)
2A13
 
1A2b 27 ± 2d 9.7 ± 0.3 d 0.4 1 
2A13 11 ± 2 3.8 ± 0.1d 0.4  1 
   A117V  48 ± 6d 29 ± 1 d 0.6 1.5 
   A213S  21 ± 3d 2.14  ± 0.06 d   0.1 0.3 
   M365V  20 ± 5d 0.93 ± 0.05 d 0.05 0.1 
   L366I  36 ± 5d 13.7  ± 0.6 d 0.4 1 
   H372R  5 ± 1d 1.91 ± 0.06 d 0.4 1 
2A6 N.D.c N.D.c N.D.c N.D.c 
   I208S/I300F/G301A 39 ± 7d 0.98 ± 0.06 d 0.03 0.08 
   I300F/G301A/S369G 4.9 ± 0.5d 0.89 ± 0.01 d 0.2 0.5 
   I208S/I300F/ 
G301A/G369S 
10.3 ± 0.8 2.88 ± 0.04 d 0.3 0.8 
Table 4.3.  Kinetic Parameters for CYP1A2, CYP2A13, and mutants of CYP2A13 and 
CYP2A6a. 
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Figure 4.3.  Phenacetin metabolism by CYP1A2, CYP2A13, mutant 
proteins.  Curves represent a global fit of two independent experiments with 
each point performed in triplicate. 
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As a result, the catalytic efficiency of the triple mutant containing I208S was much 
lower than that of the triple mutant containing S369G.  The quadruple mutant 
CYP2A6 I208S/I300F/G301A/S369G had a catalytic efficiency very similar to 
CYP2A13, with an almost identical Km and a slightly reduced kcat (Figure 4.3, panel 
C). 
 Since phenacetin has been used as a marker substrate for CYP1A2, the full-
length version of CYP1A2 (generous gift from Dr. Guengerich) was characterized in 
addition to the CYP2A13 and CYP2A6 mutant proteins.  Both CYP1A2 and 
CYP2A13 had the same catalytic efficiency of ~0.4 µM-1min-1 although their catalytic 
parameters varied considerably (Table 4.3).  CYP1A2 had a kcat of 9.7, approximately 
three times greater than the kcat of CYP2A13.  However, CYP1A2 also had a Km 
value that was three times greater than CYP2A13 (Figure 4.3, panel A). 
Discussion 
 The metabolism assay for phenacetin O-deethylation verified that amino acids 
at positions 208, 300, 301, and 369 are important for phenacetin metabolism.  
Mutation of the 300 or 301 amino acids alone nearly eliminated phenacetin 
metabolism in CYP2A13, while mutations at positions 110, 208, and 369 all 
significantly reduced phenacetin metabolism activity such that kinetic parameters 
could not be determined for any of these mutants.  Other mutant enzymes either 
reduced phenacetin metabolism to a lesser degree, as is the case for mutations at 213, 
365, and 374, or increased the rate of phenacetin metabolism (117 and 366).   
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 Substitution of single CYP2A13 residues into CYP2A6 had very little effect 
on phenacetin metabolism activity.  Therefore, we concluded that the ability of 
CYP2A13 to metabolize phenacetin was likely the result of several combined 
differences from the CYP2A6 active site.  In order to explore this possibility, a series 
of multiple mutations were generated that involved mutating residues 208, 300, 301, 
and 369 (those with the lowest activity in CYP2A13 at 250 µM phenacetin).  
Incorporation of these residues resulted in additive increases in phenacetin activity.  
The two triple mutant proteins (CYP2A6 I208S/I300F/G301A and CYP2A6 
I300F/G301A/S369G) both had significant phenacetin activity of ~1 pmol/min/pmol 
at 250 µM phenacetin.  Although both mutant enzymes had reduced catalytic 
efficiency compared to CYP2A13, the triple mutant 2A6 I300F/G301A/S369G had a 
Km value half that of the wild type CYP2A13.  The quadruple mutant containing 
mutations at residues 208, 300, 301, and 369 resulted in an enzyme with a Km nearly 
identical to that of CYP2A13 and a kcat ~80% of CYP2A13.  The fact that substitution 
of four CYP2A13 residues into CYP2A6 creates an enzyme with phenacetin O-
deethylation activity and kinetic parameters very similar to CYP2A13 indicates that 
these four residues are largely responsible for the ability to metabolize phenacetin in 
human CYP2A enzymes. 
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Conclusion 
 We hypothesized that a few amino acids may be responsible for CYP2A 
substrate selectivity.  Consistent with this hypothesis, the phenacetin metabolism data 
indicates that just four amino acids, 208, 300, 301, and 369, seem to mediate 
phenacetin metabolism in the CYP2A enzyme family.  Single amino acid 
substitutions at these positions in CYP2A13 resulted in enzymes with little to no 
phenacetin metabolism activity.  More than one of these substitutions are necessary 
for phenacetin metabolism as illustrated by the observations that none of the CYP2A6 
single mutants had significant increases in phenacetin metabolism compared to the 
wild type CYP2A6 enzyme.  Increases in phenacetin metabolism were observed when 
multiple mutations are made at these positions.  Mutations at amino acid 300 and 301 
alone resulted in a CYP2A6 enzyme with phenacetin metabolism activity ~8-fold 
greater than the wild type CYP2A6 (Table 4.2).  The quadruple mutant CYP2A6 
I208S/I300F/G301A/S369G had activity ~38-fold greater than the CYP2A6 enzyme.  
Further more, the quadruple mutant had a Km nearly identical to that of CYP2A13 and 
a catalytic efficiency ~80% of CYP2A13.  These results indicate that the substitution 
of just four amino acids is sufficient to change the active site environment of 
CYP2A6 enough to accommodate phenacetin as a ligand.  A logical next step in this 
analysis was molecular modeling studies with phenacetin and the known CYP2A13 
crystal structure. 
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Chapter 5. 
 
Molecular Modeling of Phenacetin in CYP2A13 
 
Introduction: Molecular Modeling in Cytochromes P450 
 
 Molecular modeling has been a powerful tool in understanding protein 
function.  The most common types of molecular modeling applied to cytochrome 
P450s include homology modeling for cytochromes P450 for which a crystal 
structure is not available, molecular docking to approximate ligand orientation, and 
3D quantitative structure-activity relationship (QSAR) models (1-7).  Since the 
xenobiotic-metabolizing cytochrome P450 enzymes each bind a number of different 
substrates with relatively low affinity (µM), molecular modeling of cytochromes 
P450 has some unique challenges.  Many cytochrome P450 substrates are 
metabolized at more than one site, suggesting multiple binding orientations, this 
further emphasizes the difficulties of molecular docking with cytochromes P450.  
Despite the low substrate affinity and multiple binding orientations, molecular 
modeling still offers a way to visualize possible ligand orientations within an active 
site.  For this reason, we applied molecular docking simulations to CYP2A13 using 
phenacetin as the ligand.   
We selected Surflex Dock to implement docking simulations.  Surflex Dock 
utilizes Hammerhead’s empirical scoring function (8) and incremental construction of 
the ligand around flexible bonds leading to high affinity docked conformers of 
phenacetin.  The first step is the construction of a protomol or prototypical molecule 
that represents the active site of the enzyme as mapped by probes complementary to 
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the active site surfaces.  For example, molecule moieties that can act as a hydrogen 
bond donor (NH), acceptor (OH), or hydrophobic regions (CH4) are matched to 
amino acids found in the active site.  The active site cavity can be defined either as 
the largest cavity detected in the enzyme or by using the coordinates of a ligand in the 
active site defined by a crystal structure.  Docked conformers are then incrementally 
constructed into this protomol and scored on the basis of hydrophobic, polar, 
repulsive, and entropic interactions as well as solvation between pairs of exposed 
protein-ligand atoms with a van der Waals surface distance of less than 2 Å 
(www.tripos.com).  
Methods: Surflex Docking 
The CYP2A13 enzyme used in the docking study was prepared from the 
crystallographic coordinates of PDB 2P85 (9) by protonating and adding Gasteiger-
Marsili charges in SYBYL (10).  Only molecule A was used.  Both orientations of the 
indole active site ligand and waters (except for the water hydrogen bonded to N297) 
were deleted.  The indole ligands (indole 501 and 507 as numbered in PDB 2P85) 
were prepared by protonating and adding Gateiger-Marsili charges and were saved as 
separate files for use in identifying the active site cavity. The ligand phenacetin was 
generated starting from the coordinates of indole ligand, protonated in SYBYL (10), 
and structurally optimized using the Tripos Force Field (11) (Gasteiger-Marsili 
electrostatics (12) with an 8.0 Å nonbonding interaction cutoff; default convergence 
thresholds).   
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Three different docking simulations were completed using Surflex Dock.  The 
only difference between the three simulations was the method used to define the 
active site before generating the protomol file.  The first simulation utilized indole 
501, the second used indole 507, and the third used Surflex Dock’s automatic cavity 
detection (Figure 5.1).  The protomol files using indole 507 and automatic cavity 
detection were the most similar, and differed from the protomol file generated with 
indole 501 by only one additional hydrogen bond acceptor probe.  This small 
difference appeared to be significant in the docking of phenacetin.  The results from 
the protomol file generated by indole 507 and automatically gave very similar 
conformers of phenacetin.  Several of these conformers were hydrogen bonded to 
N297, and approximately half the conformers were consistent with the generation of 
the metabolite acetaminophen.  In contrast, the conformers generated using indole 
501 were not inconsistent with acetaminophen generation.  Additionally, only one of 
the conformers in the indole 501 trial had an orientation allowing a hydrogen bond 
between phenacetin and N297, a residue that has been shown in crystal structures of 
both CYP2A13 and CYP2A6 to form hydrogen bonds with several different ligands 
(9,13).  Since the results from the automatically generated protomol file and the 
protomol file generated with indole 507 were consistent with the known metabolite 
and were in strong agreement, the results for indole 507 were analyzed further for 
structural insights into phenacetin binding. 
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Figure 5. 1.  Protomol files generated by Surflex Dock.  A.  The protomol generated 
by indole 501.  B.  The protomol generated by indole 507.  C.  The protomol 
generated on automatic cavity detection.  Protomols in panels B and C have three 
hydrogen bond acceptor probes, while the protomol in panel A only has two.  The 
acceptor probes (OH) have a red oxygen, the donor probes (NH) have a blue nitrogen, 
and the CH4 probes are pink in panel A and green in panels B and C. 
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N297 
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Results 
Docking of phenacetin into CYP2A13 (PDB 2P85) and examination of the top 
ten scoring conformations from the protomol generated from indole 507 revealed two 
general types of orientations in the active site (Table 5.1).  Five conformers were in 
positions oriented with the ether toward the heme iron, consistent with the observed 
acetaminophen metabolite (Figure 5.2, panel A).  In contrast, the second type of 
orientation had the amide and ethoxy ends swapped, orientating the amide toward the 
heme (Figure 5.2, panel B).  All of the conformations were within 1 log unit from one 
another in their total Surflex score, which is a compilation of protein-ligand atomic 
surface distance interactions including steric, polar, entropic, and solubility (Table 
5.1). 
The five conformers oriented with the ether toward the heme iron primarily 
orient the phenacetin phenyl ring alongside the I helix between A301 and F300 and 
perpendicular to the heme, with the amide oxygen within hydrogen bonding distance 
to N297.  Two of these conformers adopt an identical orientation with the carbon 
adjacent to the ether oxygen oriented for hydrogen abstraction and rebound during O-
deethylation (H-Fe, ~2.9 Å, pink sticks in Figure 5.2, panel A).  The third conformer 
(blue sticks in Figure 5.2, panel A) overlaps in terms of the phenyl ring and amide 
components, but differs in the conformation of the flexible alkyl chain.  Simple 
rotation about the phenyl-oxygen bond in this conformer would also orient the 
hydrogens of the subterminal carbon for O-dealkylation.  The fourth conformer places 
the phenyl group alongside the I helix and differs from the other three in that the 
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terminal carbon is closest to the iron.  The fifth conformation places the phenyl ring 
nearly parallel to the heme with the ether oxygen directly over the iron and maintains 
a hydrogen bond to the N297 residue (Figure 5.2, panel B).   
The five phenacetin conformers with the amide end oriented towards the heme 
iron belong to two subtypes.  In two conformers the ether oxygen can hydrogen bond 
with N297 (hydrogen bonding distance 2.75-3.22 Å), whereas in the other three 
orientations distance from N297 was greater than 3.5 Å (Figure 5.3, panel C).  These 
conformers would be more consistent with N- or C-hydroxylation on the amide end 
of phenacetin.  This would lead to metabolites that have been previously identified for 
CYP1A2 (14) or in rats, rabbits, and hamsters (15-17), but have not been attributed to 
human 2A enzymes. 
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Table 5.1.  Orientations and log KD values for the top ten scoring conformers. 
Conformation Scoring 
Funtion** 
(kD) 
Orientation for 
metabolism 
H-bond 
to N297 
(Å) 
Metabolite 
Proposal from 
Orientation 
1 3.53 ether group toward 
heme 
3.22 Acetaminophen 
2 3.26 ether group toward 
heme (H 4.43 Å from 
heme) 
2.68 Acetaminophen 
3 3.18 amide group toward 
heme 
2.75 Acetol 
4 3.00 amide group toward 
heme  
* Acetol 
5 2.97 amide group toward 
heme 
* Acetol 
6 2.87 amide group toward 
heme  
2.75 Acetol 
7 2.74 ether group toward 
heme  
2.75 Acetaminophen 
8 2.74 ether group toward 
heme 
2.75 Acetaminophen 
9 2.73 amide group toward 
heme 
2.75 Acetol 
10 2.63 ether group toward 
heme  
* Acetaminophen 
*A distance of greater than 3.5 Å to N297 is used to define the upper limit in 
hydrogen bonding. 
** Scoring function includes terms to account for hydrophobic, polar, repulsive, 
entropic, and solvation of exposed protein and ligand atoms.  The term is given in  
-log(KD) and is a measure of binding affinity. 
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Figure 5.2.  Molecular docking of phenacetin into the active site of CYP2A13 
(blue, PDB 2P85) leads to two types of orientations.  In all pictures, the heme is 
white with red iron and the view is in the active site with the I helix at the back.   
Black dashed lines indicate hydrogen bonding to N297.  A. Orientations of 
phenacetin that place the ether oxygen toward the iron and would result in 
acetaminophen as the metabolite (pink, blue, and yellow). Phenacetin with pink 
carbons (two conformers) represents the orientation most optimally oriented for 
hydrogen abstraction from the alkyl subterminal carbon and O-deethylation to 
form acetaminophen.  B.  Two additional orientations that place the ether group 
by the heme (green and yellow).  C. Orientations of phenacetin with the amide 
near the heme (orange and purple).  The orange conformer represents two 
conformers and the purple conformer represents the other three conformations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
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Discussion 
Three of the top ten conformers in our molecular modeling simulation were 
very consistent with the phenacetin metabolite observed for CYP2A13 (Figure 5.2, 
panel A).  We cannot exclude the possibility that the other conformers observed in 
our molecular modeling simulation are not viable orientations for metabolism because 
many cytochromes P450 are able to metabolize a given substrate into more than one 
metabolite.  This has been observed for CYP1A2 with phenacetin (14).  Using our 
current method of metabolite detection, absorbance, only acetaminophen was 
observed.  However, it is possible that by altering our detection method or using more 
sensitive techniques we could observe other minor metabolites.  This is one possible 
area for further research.  For the purposes of identifying possible reasons for 
phenacetin metabolism and binding by CYP2A13 but not CYP2A6, we analyzed the 
conformer most consistent with generation of the acetaminophen metabolite. 
We aligned the structure of CYP2A6 (molecule A) to the CYP2A13 
(molecule A) in using secondary structure matching (SSM) alignment in Coot (18), 
permitting a graphical overlay in Pymol (Figure 5.3).  This way potential structural 
reasons for phenacetin binding differences in CYP2A13 and CYP2A6 could be 
observed.  Experimentally, we have determined the four residues 208, 300, 301, and 
369 mediate phenacetin metabolism in CYP2A13.  This was further established in 
that the CYP2A6 quadruple mutant containing the CYP2A13 amino acids at these 
positions had phenacetin O-deethylation activity and kinetic parameters similar to 
those of CYP2A13. 
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Figure 5.3.  Comparison of the active site of CYP2A6 (brown, PDB 1Z10) 
and the active site of CYP2A13 (blue, PDB 2P85) containing the docked 
phenacetin conformer most ideally located for O-dealkylation (pink). The 
four residues shown experimentally to be most important for phenacetin 
metabolism and binding are labeled in bold.  The hydrogen bond to Asn297 
is illustrated by a dashed black line.   
 
2.75 Å 
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Two of these residues, 300 and 301, are located on the I helix near the ligand.  In 
CYP2A13, residue 300 is a phenylalanine whereas it is an isoleucine in CYP2A6.  
Although the phenylalanine is larger is size, its planarity places the side chain further 
away from the active site, leading to more space within the CYP2A13 active site 
cavity compared to CYP2A6 (Figure 5.4).   
CYP2A13 contains an alanine at residue 301, which is also larger than the 
glycine found in CYP2A6.  The slightly larger alanine at 301 may improve 
hydrophobic interactions between the enzyme and ligand (Figure 5.3).   
The third residue that affects substrate enzyme interactions is residue 208.  In 
CYP2A6 this residue is a bulky isoleucine and it is directed towards the 300 residue 
within the active site cavity (Figure 5.3).  However, in CYP2A13 a much smaller 
serine is present.  The substitution to the smaller serine in CYP2A13 may permit the 
planer phenylalanine found at position 300 to locate with the phenyl group in the 
volume occupied by the isoleucine in CYP2A6.  Orientation of the phenylalanine side 
chain away from the active site may not be possible without the substitution at residue 
208 to a smaller amino acid.  This residue may also be involved in the reorientation of 
the adjacent conserved phenylalanine 209 (9).  The conserved F209 forms part of the 
active site cavity ceiling, and from an overlay of the CYP2A active sites, it is 
apparent that this residue’s position can substantially increase or decrease active site 
volume (Figure 5.4). 
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Figure 5.4.  Stereo view comparison of the active site cavities for CYP2A6 
(PDB 1Z10, gold protein and gold mesh) and CYP2A13 (2P85, blue 
protein and blue mesh), as determined using Voidoo with a 1.4 Å3 probe 
(http://xray.bmc.uu.se/).  In the CYP2A13 active site the phenacetin 
conformation most ideally oriented for O-dealkylation is shown (sticks 
with pink carbons).  Steric clashes between CYP2A6 and the phenacetin 
are evident, particularly with CYP2A6 residues 300, 209, and 370.  These 
clashes are relieved by substitution or repositioning of the CYP2A13 
amino acids at those positions, which alter the active site volume in ways 
that would facilitate phenacetin binding in this orientation. 
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Reasons for the importance of G369S to phenacetin binding and metabolism 
are likely indirect.  Neither residue appears to change the size of the CYP2A active 
site cavity as the serine side chain found in CYP2A6 is located below the plane of the 
heme and is not part of the active site wall.  In CYP2A6, the serine side chain does 
participate in a hydrogen bond to one of the propionate oxygens that the glycine in 
CYP2A13 is unable to fulfill. However, in CYP2A13 this same interaction is 
conserved by a water molecule hydrogen bonding to the propionate oxygen (9,13).  
The water molecule is stabilized by additional hydrogen bonding to the L370 
backbone amide and carbonyl.  It is possible that instead the substitution to the 
smaller, more flexible glycine found in CYP2A13 may allow the adjacent conserved 
residue L370 more flexibility.  In all of the CYP2A13 molecules, L370 is found 
oriented toward the protein backbone, away from the active site cavity.  However, in 
CYP2A6 the predominant position of the L370 side chain appears to be toward the 
active site cavity (13,19).  Only molecule A of the CYP2A6 coumarin structure (PDB 
1Z10) has an alternate conformation placing the leucine side chain toward the protein 
backbone (13,19).   
Other residues that have notable structural differences between the active sites 
of CYP2A6 and CYP2A13 include 117, 366, and 365.  Mutation of these residues did 
alter the activity of CYP2A13 mutants.  In particular, the mutations A117V and 
L366I actually caused increased phenacetin binding affinity and metabolism. The 
increased size of the valine at position 117 may encourage hydrophobic interaction 
and/or optimal substrate positioning.  In contrast, the L366I mutation may actually 
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result in more space available to the ligand because of a change in the side chain 
orientation.  The amino acid found at position 366 forms part of the active site wall 
for both CYP2A enzymes; however, the placement of the methyl group off of the beta 
carbon in the isoleucine side chain found in CYP2A6 allows for an increase in active 
site volume available to ligand (Figure 5.3).  Mutation of residue 365 to the smaller 
valine found in CYP2A6 decreased both metabolism and binding affinity.  V365 in 
CYP2A6 is not a part of the active site cavity while the larger methionine found at 
this position in CYP2A13 forms part of the active site wall. 
The hypothesis that changes in the active site size may be largely responsible 
for the difference in phenacetin recognition between CYP2A13 and CYP2A6 is 
further supported by comparing the overall active site volume (Figure 5.4).  The 
active site of CYP2A13 (370 Å) is larger than that of CYP2A6 (260 Å) (9,13).  In 
particular, an increase in space available to the ligand by the mutations can be seen by 
residue 300, 209, and also to a lesser degree near residues 370, 366, and 365 (Figure 
5.4).  Of particular note is that the model phenacetin molecule does not completely fit 
into the active site volume of CYP2A6 near residue 300.  The difference in volume 
and steric clash around residue 300 indicates that the difference in CYP2A phenacetin 
metabolism may be largely due to steric constraints in the CYP2A6 active site (Figure 
5.4).  
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Conclusion 
The molecular docking of phenacetin into CYP2A13 gives some structural 
insight as to why residues 208, 300, and 301 are important for phenacetin 
metabolism.  Examination of the active site void volumes of both CYP2A enzymes 
with one of the phenacetin conformers clearly shows that the phenacetin molecule 
cannot fit into the CYP2A6 active site in the conformation that was favored in the 
CYP2A13 modeling study (Figure 5.4).  Closer examination of the active site void 
overlay in Figure 5.4 indicates that the active sites seem to have the greatest variation 
by the amino acids at position 117, 209, 300, 366, and 370.  It is likely that 
substitution at residue 208 or 369 result in indirect effects on the position of other 
amino acid side chains, possibly the orientation of residues 209 and 370.  It may be 
possible to determine the affect of the mutations at residues 208, 300, 301, and 369 
with a crystal structure of CYP2A6 containing these mutations. 
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Chapter 6. 
 
Structure of CYP2A6 I208S/I300F/G301A/S369G complexed with 
Phenacetin 
 
Introduction 
 The molecular modeling study discussed in chapter 5 offered potential insight 
into why the residues at 208, 300, 301, and 369 are important for CYP2A phenacetin 
metabolism.  However, due to the nature of molecular modeling with cytochromes 
P450 and because molecular modeling may not accurately predict all the potential 
structural changes mediated by multiple mutations, we decided to pursue a crystal 
structure of the quadruple mutant.  We obtained a 2.15 Å crystal structure of the 
mutant CYP2A6 I208S/I300F/G301A/S369G protein with phenacetin in the active 
site.  This structure, combined with the known structures of the CYP2A6 and 
CYP2A13 wild type enzymes, verifies the structural basis for the roles of amino acids 
at positions 208, 300, 301, and 369 in phenacetin metabolism.  This structure also 
validates the molecular modeling study.  
Crystallography Methods 
Purification Alterations: The CYP2A6 I208S/I300F/G301A/G369S protein used for 
crystallography was purified as described in chapter 2, except that 1% ANAPOE-35 
(Anatrace, Maumee, OH) was used instead of 4.8 mM Cymal-5 as the purification 
detergent (Anatrace, Maumee, OH).  The change in purification detergent was 
necessary to generate diffraction quality crystals, and lengthened the growth time 
from five hours for crystals purified in Cymal-5 to three days in ANAPOE-35.  This 
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protein was additionally purified on a Superdex 200 16/60 gel filtration column (GE 
Healthcare, Uppasala, Sweden) in buffer A (50 mM KPi, pH 7.4, 20% glycerol, 0.5 
M NaCl, and 1 mM EDTA) following the CM column to ensure protein was in a 
monodisperse, monomeric state.  Fractions containing CYP2A6 
I208S/I300F/G301A/G369S were pooled and concentrated by centrifugal 
ultrafiltration with 5 mM phenacetin in buffer A.  At this concentration, a partial 
spectra shift from the soret of ~416 nm to ~392 nm was observed.  Due to solubility 
problems, we were unable to add more than 5 mM of phenacetin to the protein.  Prior 
to crystallization, a final concentration of 0.2% ANAPOE-X-405 (Anatrace, Maumee, 
OH) was added to the concentrated protein.    
Protein Crystallization, Data Collection, and Structure Determination:  The 
hanging drop diffusion method was used to grow crystals of 100 µM CYP2A6 
I208S/I300F/G301A/G369S with 5 mM phenacetin.  A 2µL of the protein solution (1 
µL 100 µM CYP2A6 I208S/I300F/G301A/G369S and 1 µL of the equilibration 
solution) was equilibrated against 750 µL of equilibration solution (30% PEG 3350, 
0.10 M Tris, pH 8.5, and 0.2 M ammonium sulfate). The protein crystals grew in a 
mixture of plates and rods that appeared to be mature after four days at 20ºC.  Data 
was collected on one medium sized rod.  Prior to data collection, crystals were flash 
cooled in liquid nitrogen after being immersed in a cryoprotectant consisting of 350 
µL of synthetic mother liquor, 350 µL of buffer A, and 300 µL of 100% ethylene 
glycol.  A data set was collected from a single crystal at beamline 9-2 at the Stanford 
Synchrotron Radiation Laboratory (Stanford, CA) using a 0.98 Å wavelength and 
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temperature of 100 K (Figure 6.1).  The best diffraction data was collected by 
centering the X-ray beam on the side of the rod protruding from the loop (Figure 6.1).  
One hundred and four degrees with 1º oscillations and 5 second exposure/oscillation 
were collected (Figure 6.1). Data processing was completed using Mosflm (1) and 
Scala (2).  The CYP2A6 I208S/I300F/G301A/G369S mutant structure was solved by 
molecular replacement with the program PHASER (3) using CYP2A6 complexed 
with coumarin (PDB 1Z10, molecule B) with the ligand and water molecules 
removed as the search model.  Model building and refinement were done iteratively 
using COOT (4) and REFMAC5 (5) in the CCP4 suite (6).  The final model had an R 
value of 0.21 and Rfree value of 0.27 with four protein monomers and four heme 
prosthetic groups in the asymmetric unit. Molecules A, B, and D of the asymmetric 
unit contained well-defined electron density above the heme prosthetic group, but 
molecule C did not, so only three molecules of phenacetin were modeling in.  Data 
collection and processing statistics are provided in Table 6.1. 
 97 
 
 
 
 
Figure 6.1.  Data collection images.  A. Snapshot of the rod shaped CYP2A6 
I208S/I300F/G301A/S369G crystal that the data set was collected on in the loop 
during data collection. The white box around the protruding end of the crystal 
indicates the area of the crystal within the X-ray beam. Data was collected for a total 
of 104 degrees. B. An x-ray diffraction images at zero degree oscillation.     
               
A. 
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Table 6.1.  Data collection and refinement statistics. 
 
 CYP2A6 I208S/I300F/G301A/S369G 
with Phenacetin 
Data collection  
Space group P21 
Cell dimensions  
    a, b, c (Å) 70.8, 159.1, 104.0 
   α, β, γ (°) 90.0, 92.1, 90.0 
Resolutiona (Å) 87.04 - 2.15 (2.21 - 2.15) 
Total observationsa 270986 (19484) 
Unique reflectionsa 121786 (8964) 
Completenessa (%) 97.8 (97.5) 
Rsyma,b 0.059 (0.357) 
I/σIa 10.5 (1.6) 
Refinement  
Resolution (Å) 87.04 - 2.15 
No. reflections 115652 
R/Rfree (%) 21.1/26.9 
No. atoms  
    Protein 15029 
    Ligand 39 
    Heme 172 
    Water 297 
B-factors (average)  
    Protein 39.2 
    Ligand 66.6 
    Heme 27.2 
    Water 35.4 
Rms. deviations  
    Bond lengths (Å) 0.014 
    Bond angles (°) 1.5 
a  Values in parentheses are for highest-resolution shell. 
b 
! 
Rsym = "hkl"i Ii(hkl) # I(hkl) /"hkl"iIi(hkl)  
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Structure Validation and Analysis:  The CYP2A6 I208S/I300F/G301A/G369S 
structure was validated using the programs WHAT-IF (7) and PROCHECK (8).  The 
Ramachandran plot showed 90.7% of residues in the most favored regions, 8.6% in 
the additional allowed regions, 0.4% in the generously allowed regions, and 0.2% in 
the disallowed regions. F42 was in the disallowed region for all four molecules, but 
was clearly defined in the 2|Fo|-|Fc| electron density map.  This was consistent with 
previous structures of CYP2A6, all of which contained F42 in the disallowed region  
(9, 10). All voids used in structural analysis were calculated using VOIDOO (11) 
with a probe radius of 1.4 Å and a grid mesh of 0.3 Å. 
Results: Structure Analysis 
The overall tertiary structure of the CYP2A6 quadruple mutant was very 
similar to both wild type CYP2A6 and CYP2A13 with root mean squared deviations 
(r.m.s.d.) of the Cα atoms of 0.39 and 0.47 Å, respectively.  These r.m.s.d. variations 
were comparable to the r.m.s.d. between the four molecules of the CYP2A6 
quadruple mutant asymmetric unit (0.29 to 0.48 Å). The greatest variation in tertiary 
structure was observed in the solvent exposed loops. 
All four mutations were clearly evident in the electron density. The mutated 
side chains F300 and A301 were in the same orientation in all four monomers.  Both 
F300 and A301 are found on the I helix.  F300 forms the top portion of the active site,  
whereas A301 forms part of the side (Figure 6.2, panel A).  The S208 mutation is 
directly above F300.  The S208 side chain is rotated toward the active site in 
molecule A, while in molecules B, C, and D it is angled away from the active site 
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(Figure 6.2, panel B).  The rotation of this side chain does not appear to alter the 
active site volume as molecules A and C had nearly identical active site volumes. 
In addition, electron density corresponding to phenacetin was present in three 
of the four protein active sites.  This density indicated phenacetin oriented with the 
acetamide directed toward residue 300 and the ethoxy group oriented toward the 
heme iron, consistent with the experimentally observed O-deethylation (Figure 6.2, 
panel A).  Phenacetin appears to have some flexibility in orientation as the molecule 
varied somewhat between all three molecules, in terms of the plane of the phenyl ring 
and the flexible ethoxy tail (Figure 6.1, panel B).  There is, however, a conserved 
hydrogen bond (2.9-3.14 Å) between N297 for each molecule and the amide oxygen 
of phenacetin and the distance from the subterminal carbon and the iron was 
maintained at 4-4.5 Å in each monomer. 
The orientation of the L370 side chain varied between molecules.  Molecule A 
and C had the leucine side chain oriented so that it is rotated away from the 
phenacetin (Figure 6.2, panel B).  In monomer A, the terminal carbon of phenacetin 
ethoxy chain projects toward this side chain and the repositioning of L370 makes 
additional space available to the ligand.  This side chain had an alternate 
conformation only in monomer A of four monomers in the CYP2A6 structure 
complexed with coumarin (PDB 1Z10) (10).  Due to the rotation of L370 away from 
the active site, the active site volumes for molecules A and C are 300 Å3 and 297 Å3, 
respectively.  In contrast, the active site volume is reduced in molecules B (270 Å3) 
and D (272 Å3) (Figure 6.2, panel C).  Corresponding to the reduced volume 
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available, in molecule B and D the terminal carbon of the phenacetin ethoxy side 
chain projects toward the I helix.  Replacement of the adjacent S369 by the glycine 
present in CYP2A13 may result in additional flexibility for L370 in the CYP2A6 
mutant and the CYP2A13 wild type enzyme. 
 The active site of the quadruple mutant is primarily hydrophobic, with the 
hydrophilic residue N297 as the most orientating feature.  Despite the small active 
site volume, phenacetin has some degree of flexibility within the active site, as 
indicated by its different orientation in the three protein molecules.   
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Figure 6.2. The CYP2A6 
I208S/I300F/G301A/G369S 
structure.  A.  Electron 
density surrounding the 
phenacetin ligand found in 
molecule B of the CYP2A6 
I208S/I300F/G301A/G369S 
structure (2|Fo|-|Fc|). B.  
Structural overlay of the 
non-identical protein 
molecules found in the 
CYP2A6 
I208S/I300F/G301A/G369S 
asymmetric unit, 
highlighting the differences 
between the three 
phenacetin molecules and 
L370 positions.  Molecules 
A (green), B (yellow), and 
D (blue) contain one 
molecule of phenacetin, 
while molecule C (pink) did 
not have electron density for 
phenacetin.  C.  Active site 
volume comparison between 
molecule A (green mesh, 
300 Å3) and molecule B 
(yellow mesh, 270 Å3).  The 
difference in active site 
volume among the four 
CYP2A6 quadruply-mutated 
protein molecules appears to 
depend largely on the 
position of L370.  Black 
dashed lines indicate 
hydrogen bonding to N297.   
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Comparison of the CYP2A6 I208S/I300F/G301A/G369S Structure to the 
Structures of Wild Type CYP2A6 and CYP2A13  
Insight into how mutations at residues 208, 300, 301, and 369 can 
significantly alter CYP2A functionality is gained by comparing the CYP2A13, 
CYP2A6, and the CYP2A6 I208S/I300F/G301A/G369S active sites (Figure 6.3).  
CYP2A6 and CYP2A13 have some of the smallest human P450 active sites, with a 
volume of 214-230 Å3 for the four CYP2A6 molecules (PDB 1Z10) and a volume of 
~304 Å3 (PDB 2P85) for CYP2A13 (12).  The four quadruple mutant molecules had 
intermediate volumes from 270 – 300 Å3, depending primarily on the L370 
conformation.   
The residues 300 and 301 are critical in phenacetin binding and metabolism, 
consistent with their close interaction with phenacetin in the crystal structure.  The 
planer phenylalanine at position 300 in CYP2A13 and the quadruple mutant results in 
additional active site space in this region to accommodate the phenacetin acetamide.  
In contrast, the bulkier isoleucine in CYP2A6 actually results in a decrease in active 
site volume available to the ligand because the isoleucine side chain decreases the 
active site area available to ligand near residue 300.  This is evident when viewing the 
active site cavities as a steric clash occurs between CYP2A6 I300 and the terminal 
carbon of the amide end of phenacetin (Figure 6.4).  
Both the CYP2A13 and CYP2A6 quadruple mutant structures place the 
methyl side chain of alanine at position 301 toward the face of phenacetin just 
proximal to the ring. 
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Figure 6.3. Active site comparison of CYP2A6 (purple, PDB 1Z10, molecule B), 
CYP2A6 I208S/I300F/G301A/G369S with phenacetin (green, molecule A), and 
CYP2A13 (brown, PDB 2P85, molecule A). The four residues mutated in the 
CYP2A6 quadruple mutant, identical to the residues found in CYP 2A13, are labeled 
in bold.  The hydrogen bond from phenacetin to N297 is shown as a dashed black 
line.   
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Figure 6.4. Comparison of the active site cavities of CYP2A6 (purple protein and 
mesh, PDB 1Z10), CYP2A13 (brown protein and mesh, PDB 2P85), and CYP2A6 
I208S/I300F/G301A/G369S (green protein and mesh) in stereo view.  Steric clashes 
between the phenacetin and purple CYP2A6 residues I300, F209, and L370 are 
evident. 
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 It might seem counterintuitive that the smaller glycine does not improve substrate 
metabolism and binding.  However, it may be that the glycine found in CYP2A6 
removes necessary packing interactions to stabilize phenacetin in the active site and 
adds additional flexibility to the I helix that is not favorable.  
The third mutated residue essential for phenacetin metabolism is residue 208. 
In CYP2A13 and the quadruple mutant, this residue is a serine and located in helix F 
directly above residue 300.  There is a substantial reduction in size of the side chain 
compared to the isoleucine found in CYP2A6, and furthermore, S208 is torsioned 
away from the active site in the majority of the quadruple mutant molecules.  This 
also creates space that may facilitate phenyl ring of F300.  This would indirectly 
increase the space for available for phenacetin binding.  In addition, the residues at 
position 208 and 300 may alter the orientation of the adjacent conserved F209 (Figure 
6.3).  The orientation of F209 in the CYP2A6 quadruple mutant structure is identical 
to the position of F209 in CYP2A13, placing the phenylalaine away from phenacetin 
and thus creating an active site volume that better accommodates phenacetin (Figure 
6.4). 
The fourth residue, 369, is located on the opposite side of the active site 
cavity.  The serine found at this position in CYP2A6 interacts with the heme 
propionate (Figure 1.4).  In CYP2A13 and the CYP2A6 quadruple mutant, a glycine 
is found at this position.  A water molecule instead mediates the contact maintained 
with the heme propionate by the serine in CYP2A6.  Therefore, the residue at position 
369 appears to have an indirect role in phenacetin binding by modulating the 
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positioning of the adjacent L370 residue.  In CYP2A6 the adjacent residue L370 
usually projects into the active site where phenacetin would otherwise bind while this 
side chain is oriented along the loop forming the wall of the active site in CYP2A13.  
In two of the four quadruple mutant molecules, the L370 side chain is in the 
CYP2A13 position.  In the 1Z10 structure of CYP2A6, there is one molecule with 
this second CYP2A13-like orientation of L370, but the lack of steric conflicts when 
glycine is at 369 may facilitate the repositioning of L370 as seen in CYP2A13.  
Ultimately, this may promote phenacetin binding and metabolism because the volume 
is more compatible with phenacetin binding and metabolism (Figure 6.4). 
The CYP2A6 I208S/I300F/G301A/G369S crystal structure also gives 
structural insight into the two CYP2A13 mutations, A117V and L366I, that resulted 
in substantial increases in phenacetin kcat above that of the CYP2A13 wild type 
enzyme.  The first, CYP2A13 A117V, resulted in a 40% decrease in KD, a 4.5-fold 
increase in Km, and an overall two-fold increase in catalytic efficiency, suggesting 
multiple effects in binding and catalysis.  Although the quadruple mutant’s valine 
side chain projects further into the active site toward the phenacetin than the 
CYP2A13 alanine, the reduction in volume in this portion of the active site may be 
beneficial in orientating the phenacetin within the active site  (Figure 6.3).  The L366I 
mutation had a dramatically increased binding affinity, but an overall catalytic 
efficiency similar to wild type CYP2A13, with ~3.5-fold increases in both Km and 
kcat.  The residue 366 is located close to residues 365 and 369 near the alkyl chain of 
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phenacetin.  Mutation from the leucine found in CYP2A13 to the isoleucine in 
CYP2A6 would also likely increase the size of the active site cavity.  This is evident  
in the substantial increase in active site volume near this residue in the quadruple 
mutant compared to CYP2A13 (Figure 6.4). 
Validity of Molecular Modeling Experiments 
 The large degree of flexibility for phenacetin in the active site is reminiscent 
of the various orientations obtained in the molecular modeling of phenacetin docking 
into CYP2A13.   The molecular modeling placed the phenacetin molecule with either 
the ethoxy or the acetamide end orientated toward the heme with equal probability.  
When refining the CYP2A6 I208S/I300F/G301A/S369G crystal structure, we 
modeled the phenacetin molecule in both directions.  After multiple rounds of 
refinement, the phenacetin density clearly favored orientation of the ligand with the 
ethoxy end of phenacetin toward the heme.  However, we cannot exclude the 
possibility that some phenacetin molecules can bind with the acetamide end toward 
the heme as suggested by the molecular modeling study.  The molecular modeling 
program did capture several of the most defining features of phenacetin binding in the 
orientation observed in the crystal structure.   
A majority of the top ten orientations in the molecular modeling study 
maintained a hydrogen bond with N297, which was observed in all three phenacetin 
molecules in the crystal structure.  In addition, the relative location of phenacetin is 
consistent with that of the phenacetin molecules in the crystal structure (Figure 6.5).  
The plane of the phenyl ring also varied between the three molecules of the 
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asymmetric unit, indicating that more than one plane is allowed for ligand orientation 
within the active site. 
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Figure 6.5.  The overlay of the CYP2A6 I208S/I300F/G301A/S369G mutant 
molecule D (blue) and the CYP2A13 molecule A (orange).  The phenacetin molecule 
found in the CYP2A6 quadruple mutant is also colored blue.  Two of the phenacetin 
conformers from the CYP2A13 molecular modeling simulation were also included 
for comparison (yellow and pink).  Hydrogen bonds are indicated by black dashed 
lines. 
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Conclusions 
 The crystal structure of CYP2A6 I208S/I300F/G301A/S369G complexed with 
phenacetin provided experimental validation into the importance of residues 208, 300, 
301, and 369 on phenacetin binding and metabolism by human CYP2A enzymes.   
Comparison to the active sites of CYP2A13 and CYP2A6 crystal structures suggest 
that the ability of CYP2A enzymes to metabolize phenacetin is largely the 
culmination of steric effects of the substituted side chains themselves and their effects 
on the positions of adjacent side chains F209 and L370.  Although many of the same 
structural conclusions could be drawn by examination of the molecular docking 
results, obtaining the crystal structure was important confirmation and allowed for 
direct analysis of the four key amino acid substitutions (13).  As hypothesized, the 
substitution of the CYP2A13 amino acids found at positions 208, 300, 301, and 369 
into CYP2A6 resulted in a mutant enzyme with an active site structurally similar to 
CYP2A13. 
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Chapter 7. 
Spectral Binding Assays of CYP2A6 Multiple Mutants 
Introduction 
 To determine if the four amino acids important for mediating phenacetin 
binding and metabolism in CYP2A enzymes (chapters 3-6) also collectively mediate 
the selectivity of other CYP2A substrates, spectral ligand binding assays were 
conducted using the CYP2A6 triple and quadruple multiple mutants with coumarin, 
2´-methoxyacetophenone (MAP), phenethyl isothiocyanate (PEITC) and phenacetin 
as ligands.  These ligands were selected so the KD values could be compared to those 
determined for the single CYP2A13 mutants in chapter 3.   
Methods 
 All proteins used in this chapter were expressed and purified according to the 
protocol found in chapter 2.  The procedure for the spectral ligand binding assay is 
also found in chapter 2. 
Results and Discussion 
Spectral Binding Assays of CYP2A6 Multiple Mutants:  The largest variation in 
CYP2A binding affinity was with phenacetin as a ligand.  Phenacetin does not cause 
a significant spectral shift in CYP2A6 at concentrations up to 250 µM, while 
CYP2A13 has a dissociation constant of 34 µM (Figure 3.2).  However, both CYP  
2A6 I300F/G301A/S369G and quadruple CYP2A6 I208S/I300F/G301A/S369G 
mutants had phenacetin dissociation constants below that of the wild type CYP2A13.  
The CYP2A6 I208S/I300F/G301A mutant had a KD of 63 µM, approximately two-
 114
fold higher than wild type CYP2A13 (Table 7.1).  This indicates that substitution at 
369 has a greater effect on phenacetin binding than substitution at position 208.  
Unlike phenacetin metabolism, which required all four mutations to reach phenacetin 
O-deethylation metabolism levels similar to those of CYP2A13, the mutation of 
position 208 to the CYP2A13 residue is not required to attain phenacetin binding 
affinity similar to CYP2A13 and appears to be somewhat detrimental.  
 The ligand 2´-methoxyacetophenone also had a substantially different binding 
affinity for CYP2A13 (0.85 µM) compared to CYP2A6 (74 µM).  The CYP2A6 
triple and quadruple mutants all had binding affinities that were reduced from the 
wild type CYP2A6, with a dissociation constant of ~ 10-12 µM for the triple mutants 
and a KD value of 3.5 µM for the quadruple mutant (Table 7.1).   
 CYP2A13 and CYP2A6 have a 14-fold difference in binding affinities for 
phenethyl isothiocyanate with dissociation constants of 0.43 µM and 6.1 µM, 
respectively.  The CYP2A6 I208S/I300F/G301A mutant had slightly increased 
binding affinity compared to wild type CYP2A6 with a KD of 4.9 µM (Figure 7.1).  
The CYP2A6 I300F/G301A/S369G and CYP2A6 I208S/I300F/G301A/S369G 
mutants both had binding affinities ~ 2 µM, a value intermediate to the wild type 
enzymes.   
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Table 7.1.  KD values for wild type CYP2A enzymes and CYP2A6 multiple mutants 
with four ligands.  KD values for independent trials are in parenthesis, average of the 
two trials is below.  Phenacetin KD values represent preliminary data from one trial. 
 
Cytochrome P450 
 
MAP  
KD 
(µM) 
PEITC 
KD 
(µM) 
Coumarin 
KD 
(µM) 
Phenacetin 
KD 
(µM) 
2A6 (65, 69, 104) 
74 
(5.4, 6.9) 
6.1 
(2.7, 3.4)  
3.1 
N.D.a 
2A13 (1.0, 0.66) 
0.85 
(0.31, 0.54) 
0.43 
(2.0, 3.3) 
2.7 
(30, 35, 37) 
34 
2A6 mutants:        
  I208S/I300F/G301 (8.2, 10.7) 
9.5 
(5.8, 4.0) 
4.9 
(6.0, 4.6) 
5.3 
 
63 
  I300F/G301A/S369G (12.6, 12.0) 
12.3 
(2.3, 1.5) 
1.9 
(2.6, 3.6) 
3.1 
 
13 
I208S/I300F/G301A/S369G (2.4, 4.5)  
3.5 
(2.6, 1.5) 
2.1 
(2.5, 2.1) 
2.3 
21 
a N.D.  Not determined as only a reduced spectral shift was detected, which did not 
allow determination of KD see Figure 3.2. 
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Figure 7.1.  Binding affinity comparison of the two wild type CYP2A enzymes and 
three of the CYP2A6 multiple mutants. 
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 The binding affinity of both CYP2A13 and CYP2A6 is ~3 µM for coumarin.  
Not surprisingly, both CYP2A6 I300F/G301A/S369G and CYP2A6 
I208S/I300F/G301A/S369G mutants had a binding affinity for coumarin similar to 
the wild type enzymes (Table 7.1).  The CYP2A6 I208S/I300F/G301A mutant had a 
slightly decreased binding affinity, but this was less than two-fold change, with a KD 
of 5.3 µM.  It is notable that the single S208I mutation in CYP2A13 also caused a 
decrease in coumarin binding affinity.   
Conclusion 
 These spectral ligand binding titrations indicate that the four amino acids that 
are essential for CYP2A phenacetin binding and metabolism are also important for 
binding affinity for PEITC and MAP.  The quadruple mutant CYP2A6 
I208S/I300F/G301A/S369G had ligand binding affinities for MAP, PEITC, and 
phenacetin more similar to CYP2A13 than to the wild type CYP2A6 enzyme (Figure 
7.1).  This is consistent with the observations made during analysis of the CYP2A6 
I208S/I300F/G301A/S369G crystal structure that revealed the quadruple mutant 
active site was similar to CYP2A13 (Figure 6.4).  However, there were some 
differences between the mutant CYP2A6 I208S/I300F/G301A/S369G active site void 
and the active site void for CYP2A13.  In particular, the region around residue 117 
has more active site volume in CYP2A13 than in CYP2A6 
I208S/I300F/G301A/S369G.  Although this decrease in active site volume may have 
been beneficial for phenacetin metabolism, as indicated by the increased kcat in the 
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mutant CYP2A13 A117V (Figure 4.3), more space may be required in this portion of 
the active site for other ligands. 
Based on this spectral binding data, it may be that to completely convert the 
binding affinity of CYP2A6 to that of CYP2A13, additional residue substitution may 
be required based on the specific ligand.  In chapter 3, it is apparent that the extent of 
the effects of mutating some residues in CYP2A13 was ligand dependent.  Although 
for phenacetin, the substitution of just three amino acids, those at positions 300, 301, 
and 369, were required to convert the CYP2A6 enzyme to a binding affinity that was 
actually greater than that of CYP2A13, for other ligands the inclusion of other 
important substitutions may be necessary to gain increased binding affinity 
conversion.  For example, with the CYP2A13 mutant spectral binding studies, 
mutation of residue 117 in CYP2A13 to the valine found in CYP2A6 significantly 
decreased MAP binding affinity (Table 3.2).  The inclusion of this mutation in the 
CYP2A6 quadruple mutant could potentially result in an enzyme capable of binding 
MAP tighter.  Furthermore, residue 208, which was important for phenacetin 
metabolism, did not seem to have as much of an effect on phenacetin binding.  This 
indicates that some substitutions that affect substrate metabolism may do so in ways 
other than directly mediating substrate binding.  In order to have a complete 
understanding of the substrate specificity for these other ligands in light of the 
CYP2A active site structure, metabolism assays could be pursued in addition to the 
substrate binding studies.   
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The study described in the chapter substantiates the hypothesis that only a few 
amino acids are largely responsible for substrate selectivity differences in CYP2A 
enzymes.  For the differentially binding ligands assayed, the four mutations that were 
identified as essential for pheneacetin binding and metabolism also led to significant 
increases in binding affinity, approaching the KD values observed for CYP2A13.  
Thus, it is likely that the four residues identified (208, 300, 301, and 369) are also key 
residues that mediate CYP2A substrate specificity for other ligands.  Further study 
would be required to determine whether these residues are also essential for selective 
metabolism of these substrates and whether other residues besides these four are 
important to substrate specificity in a ligand dependent manner. 
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Chapter 8. 
A Functional Study of CYP2A13 Polymorphisms 
Introduction 
We have established in prior chapters that the difference in CYP2A substrate 
selectivity is primarily mediated by a few amino acids in or near the active site that 
differ between the two CYP2A enzymes.  However, single amino acid variants in 
regions of the protein not near the active site can also alter protein stability and the 
overall catalytic rates.  Several naturally occurring polymorphisms have been shown 
to alter substrate metabolism in CYP2A6 (1-21).  These CYP2A6 polymorphisms can 
result in reduced or eliminated rates of substrate metabolism, likely due to indirect 
effects on the protein activity or its stability. Despite the amount of research available 
on CYP2A6 polymorphisms, very few studies were available on CYP2A13 
polymorphisms.  A study conducted by Wang and coworkers utilizing Flp-In in the 
Chinese hamster ovary cell line expressing CYP2A13 was one of the few studies 
exploring the effects of CYP2A13 variants (Table 8.1) (22).  That study evaluated 
nine single amino acid variants and determined that there was not significant variation 
from wild type CYP2A13 for aflatoxin B1 or NNK-induced cell toxicity except for 
the variant R101Q, which was identified as a null variant of CYP2A13 (22). The 
Scott and Murphy labs collaborated to study the functional consequences of six 
CYP2A13 polymorphisms (R101Q, D158E, R257C, V323L, F453Y, and R434C) 
using purified CYP2A13 enzyme and analysis of coumarin binding and the α-
hydroxylation of the procarcinogens 
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Table 8.1.  The known functional changes of CYP2A13 polymorphisms. 
 
Allele Protein Change Functional Change 
A25N Unknown CYP2A13*2 
R257C Decreased coumarin 7-hydroxylation and 
NNK metabolism (24) 
No change in AFB1 and NNK toxicity (22) 
CYP2A13*3 133_134 T insert.         Unknown 
CYP2A13*4 R101Q Inactive enzyme  (22) 
CYP2A13*5 F453Y No change in AFB1 and NNK toxicity (22) 
CYP2A13*6 R494C No change in AFB1 and NNK toxicity (22) 
CYP2A13*7 R101 X Inactive enzyme (25) 
CYP2A13*8 D158E No change in AFB1 and NNK toxicity (22) 
CYP2A13*9 V323L No change in AFB1 and NNK toxicity (22) 
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 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N′-nitrosonornicotine 
(NNN) and 7-hydroxylation of coumarin (23).   
Methods 
 Each of the CYP2A13 polymorphisms (R101Q, D158E, R257C, V323L, 
F453Y, R434C, and the T133_134 insertion) were designed, expressed, and purified 
in the truncated, His tagged form according to the procedures found in chapter 2.  
Active protein could not be obtained due to protein degradation during purification 
for the CYP2A13 R101Q and T133_134 insertion variants.  The inclusion of protease 
inhibitors in the purification led to the isolation of very little CYP2A13 R101Q 
enzyme, and this protein was inactive according to the CO difference assay.  The 
other five polymorphic CYP2A13 proteins were expressed at similar levels as 
CYP2A13 wild type enzyme and yielded active protein, as indicated by the CO 
difference assay after the two-column purification.  Prior lab members Brian Smith 
and Jason Sanders were responsible for the purification of these variant proteins. 
Results and Discussion 
CYP2A13 Polymorphism Spectral Binding Affinity and Metabolism of Coumarin:  
CYP2A13 and the five variants all had very similar binding affinities for coumarin 
(Table 8.2).  The KD value for CYP2A13 wild type was determined to be 2.4 µM.  
None of the mutants had statistically different KD values.  The Murphy lab 
determined the kinetic parameters for coumarin 7-hydroxylation. None of the variants 
had a significant change in catalytic efficiency (Table 8.2). 
 123 
Table 8.2.   Coumarin binding and coumarin 7-hydroxylation by CYP2A13 and five 
variants. 
 
 Binding a  Coumarin 7-hydroxylationb 
Enzyme KD (µM) Amax  Km (µM) Kcat (pmol/min/pmol) Kcat/Km 
2A13 2.4 ± 0.7 0.037 ± 0.009  8 ± 2 0.57 ± 0.03 0.08 
R257C 2.4 ± 0.9 0.059 ± 0.005  16 ± 2c 0.52 ± 0.02 0.03 
F453Y 2.5 0.071  9 ± 1 0.51 ± 0.02 0.06 
R494C 2.1 0.054  13 ± 2c 0.66 ± 0.03c 0.05 
D158E 2.4 ± 0.6 0.069 ± 0.003  6 ± 1 0.15 ± 0.006c 0.03 
V323L 3 ± 2 0.059 ± 0.004  12 ± 1c 0.52 ± 0.02 0.04 
 
a Mean KD and Amax values are based on three independent determinations; single determinations are 
given for R453Y and R494C 
b Kinetic parameters presented as weighted means ± SE determined from three independent 
experiments conducted in duplicate, (four independent experiments for D148E) 
c Significance compared to CYP2A13 as determined by , p< 0.05 
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 CYP2A13 Polymorphism Metabolism of NNN and NNK:  The Murphy lab also 
determined kinetic parameters for NNN and NNK metabolism (Table 8.3).  
CYP2A13 catalyzes the 5′-hydroxylation of (S)-NNN to a lactol with a Km of 110 ± 
10 µM and a kcat of 3.3 ± 0.1 min-1.  All of the mutant variants had catalytic 
efficiencies for NNN at approximately the CYP2A13 wild type level although there 
was some variation in the individual kinetic parameters.  For NNK metabolism, each 
of the polymorphic variants had slightly increased Km values compared to the wild 
type CYP2A13 enzyme.  In addition, the D158E and V323L polymorphisms had 
decreased kcat values.  This led to three polymorphic variants with NNK catalytic 
efficiency decreased by more than 2-fold: D158E, R257C, and V323L.  
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Conclusion 
 None of the polymorphic variants of CYP2A13 in this study had substantial 
effects on coumarin binding and metabolism, or on NNK or NNN metabolism that 
would likely lead to significant in vitro effects.  There was a slight decrease in 
coumarin metabolism catalytic efficiency for CYP2A13 R257C and D158E.  There 
was also a 2-fold decrease in NNK metabolism catalytic efficiency for CYP2A13 
D158E, R257C, and V323L. 
The small change in catalytic efficiency for coumarin, NNK, and NNN with 
the polymorphisms is not surprising considering their locations in the CYP2A13 
enzyme. The only mutation near the active site was R101Q, which in the crystal 
structure interacts with a heme proprionate oxygen (Figure 8.1, panel A).  Therefore, 
it is logical that the mutation of this residue could result in an unstable enzyme, as 
observed in our attempts to purify the enzyme. Each of the other mutations were 
located either below the heme plane or away from the active site in solvent exposed 
areas of the protein (Figure 8.1, panel B). The insertion of a threonine between 
residues 133 and 134 is into a helix located beneath the heme. 
While it is possible that changes in amino acids away from the active site can 
still affect enzyme function, it appears that the majority of CYP2A13 polymorphisms 
have little affect on CYP2A13 metabolism.  Of the mutations we studied, R101Q and 
the threonine 133_134 insertion are likely to have the greatest effect on NNK 
metabolism, and therefore possible cancer risk, because both resulted in inactive 
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protein.  The reduction in inactive CYP2A13 protein would theoretically result in a 
decrease in the toxic metabolites produced from NNK. 
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Figure 8.1.  Cytochrome P450 2A13 (green, PDB 2P85) with the location of 
polymorphic variants with side chains shown and colored pink.  A.  Only one of the 
six polymorphic variants in this study was located within the active site cavity, this 
was the mutation of an arginine to a glutamine at position 101.  B.  The location of 
the other six polymorphisms are on the exterior part of CYP2A13. 
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Chapter 9. 
Conclusion 
 The goal of this project was to determine the structural rationale for functional 
differences between the CYP2A13 and CYP2A6 enzymes that share 94%, sequence 
identity.  Our hypothesis was that non-identical amino acids located in or near the 
active site of CYP2A13 and CYP2A6 most likely controlled functional differences.  
A number of techniques including site-directed mutagenesis, spectral binding assays, 
and metabolism assays were used to determine that four amino acids (208, 300, 301, 
and 369) largely mediate the substrate selectivity of phenacetin in the CYP2A 
enzymes.  The determination of a crystal structure of the quadruple mutant 2A6 
I208S/I300F/G301A/S369G verified that mutation of these four residues led to a 
mutant enzyme with an active site similar to CYP2A13 in terms of the orientations of 
both the mutated and conserved side chain and overall volume.  Spectral binding 
assays of single and multiple CYP2A13 and CYP2A6 mutants with MAP, PEITC, 
and coumarin indicate that the residues are also likely to be important for selective 
binding of other ligands. 
 This project provided new information about the active sites of CYP2A6 and 
CYP2A13.  We now know several residues that are key for differential ligand 
interaction and substrate metabolism.  One of the long-term goals of the Scott lab is 
the design of an inhibitor specific for CYP2A13.  The understanding of the 
cytochrome 2A family gained through this structure-function study will prove 
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valuable in our efforts to design an inhibitor for CYP2A13 that will have very low 
affinity for CYP2A6 and other cytochrome P450 enzymes. 
 We also examined some of the naturally occurring human CYP2A13 
polymorphic variants in collaboration with the Murphy lab.  Our results indicated that 
for coumarin binding and metabolism, and for NNN and NNK metabolism, 
CYP2A13 polymorphisms appear to have very little affect on substrate affinity or 
metabolism.  This suggests that the single polymorphic variants studied to date likely 
contribute little to NNK-related cancer susceptibility.  The two polymorphisms that 
could not be purified, the R101Q mutation and the insertion of a threonine between 
residues 133 and 134, may have an effect on an individual’s susceptibility to cancer 
as these polymorphisms appear to lead to inactive CYP2A13. 
 Although this collection of research has provided valuable insight into the 
CYP2A family, it also generates new questions.  We have shown that four residues 
primarily mediate selectivity for phenacetin; however, further work remains to 
determine if residues 208, 300, 301, and 369 also mediate catalytic selectivity of other 
substrates, particularly substrates of physiological importance like NNK.  In addition, 
although we have studied CYP2A6 and CYP2A13, the closely related CYP2A7 is 
currently classified as an orphan cytochrome P450.  With the knowledge of CYP2A 
enzymes gained through this study, it may be possible to determine how the CYP2A7 
structure and function (or lack thereof) relates to CYP2A13 and CYP2A6. 
